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Hiermit erkläre ich, dass die Dissertation weder als Ganzes noch in Teilen an einem an-
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Abstract
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a highly toxic, ubiquitous environmental
pollutant and regarded the most potent chemical carcinogen in experimental animals. Most
of the biological effects of TCDD are mediated by its binding to the cytosolic Aryl hydro-
carbon (Ah) receptor. The resultant alterations in gene expression have been thoroughly
characterized, but for most of the multifaceted toxic actions of the dioxin the molecular
mechanism is still unclear. Interestingly, there is recent evidence that TCDD also causes
early changes in signal transduction unrelated to altered gene activation, but this has not
been explored systematically yet. In order to address this aspect of dioxin action, a global
quantitative mass spectrometric analysis of the alterations of protein phosphorylation pre-
ceding the alterations in gene expression at the protein level (at 0.5 –2 h after the start
of exposure) was performed using 5L rat hepatoma cells as a model system. In order to
allow a precise mass spectrometric quantitation of phosphopeptides, cells were differen-
tially labelled using the SILAC (”stable isotope labelling by amino acids in cell culture”)
approach and subsequently treated with DMSO or 1 nM TCDD for 0.5, 1 and 2 h. Proteins
from control and treated cells were mixed, proteolysed, and phosphorylated peptides were
isolated by metal affinity chromatography using a combination of the SIMAC (”sequential
elution from immobilized metal affinity chromatography (IMAC)”) and the TiO2 approach.
The phosphopeptides were further fractionated by hydrophilic interaction chromatography
and quantitated and identified by liquid chromatography-tandem mass spectrometry on a
linear ion trap mass spectrometer (LTQ-Orbitrap XL).
In total, eight independent experiments were performed which resulted in the identifi-
cation of 5648 different phosphorylated peptides comprising 6573 distinct phosphorylation
sites. These peptides were derived from 2156 different phosphoproteins that were identified
using the International Protein Index (IPI) database. Phosphopeptides with abundances
statistically significantly ”regulated” by TCDD were identified by applying an empirical
Bayes moderated t-test to all peptides found at least twice for a particular exposure period
Abstract
followed by the application of the ”q-value method” for controlling the false discovery rate.
0, 4 and 6 peptides with a q-value <0.05 were identified for the exposure periods 0.5, 1
and 2 h, respectively. A volcano plot analysis indicated that the statistical threshold of q
< 0.05 was equivalent to a biological threshold of a ±1.5 fold-change in phosphopeptide
abundance. 4, 8 and 16 phosphorylated peptides which were observed in only one of the
experiments per time point and which exhibited a regulation factor >1.5 were observed
for the three exposure periods. For the majority of the identified proteins wit changes on
specific phosphorylation sites due to TCDD treatment, other phosphopeptides not showing
any regulation were observed. This observation suggest that the phosphorylation changes
were caused by the non-genomic pathway and not due to altered total levels of the re-
spective proteins. With the exception of the up-regulation of Tyr182 phosphorylation of
the MAP kinase p38alpha, none of the TCCD-induced phosphorylation changes had been
described before. One of the proteins with altered phosphorylation was the transcription
factor ARNT (aryl hydrocarbon receptor nuclear translocator), an obligate partner pro-
tein for gene activation by the Ah receptor. For the first time it was demonstrated that
TCDD upregulates Ser77 phosphorylation of ARNT. Other proteins with altered phospho-
rylation included various transcriptional co-regulators previously unknown to participate
in TCDD-induced gene activation, such as TIF1β, a co-repressor of the transcriptional
repressor KRAB, RD RNA binding protein, a protein participating in the control of tran-
script elongation, and its interaction partner ”Nuclear cap-binding protein subunit 1”, were
identified. In addition, numerous other proteins involved in functions other than transcrip-
tional regulation were identified to carry specific TCDD-”regulated” phosphorylation sites.
These proteins included, among others, six regulators of the activity of small GTPases of
the Rho and Rab families, two UBX domain-containing proteins involved in different as-
pects of protein degradation, and AHNAK, a protein implicated in the regulation of Ca2+
entry and signalling. Thus, the results of the present phosphoproteomics study shed new
light on proteins involved in the activation of gene expression and early changes in signal
transduction by TCDD and open up new directions for future research on the molecular
mechanisms of dioxin action and toxicity.
ii
Chapter 1
Introduction
1.1 2,3,7,8-Tetrachlorodibenzo-p-dioxin
2,3,7,8-Tetrachlorodibenzo-p-dioxin (TCDD) is a ubiquitous and persistent environmen-
tal contaminant with the potential to cause a broad spectrum of adverse health effects,
such as developmental defects, cardiovascular disease, diabetes, porphyria and hormonal
disturbances in human [White and Birnbaum, 2009]. In 1997, TCDD was also classified
as carcinogenic to humans by the International Agency for Research on Cancer (IARC)
[IARC, 1997]. In spite of enormous efforts to uncover the action mechanisms underlying the
various deleterious effects of TCDD and related dioxins, the precise molecular mechanisms
mediating toxicity are still largely unknown for most toxic actions of TCDD.
1.1.1 The genomic actions of TCDD
TCDD is a ligand of the so-called aryl hydrocarbon receptor (AhR), a primarily cytosolic
receptor which plays important roles in normal cell physiology [Barouki et al., 2007] and
mediates the toxic effects of TCDD [Fernandez-Salguero et al., 1996], [Bunger et al., 2008].
Receptor binding of TCDD or a wide variety of other AhR agonists, such as the carcino-
genic polycyclic aromatic hydrocarbon benzo(a)pyrene, results in the translocation of the
ligand-receptor complex into the cell nucleus and dimerization with a related protein,
the AhR nuclear translocator (ARNT). This heterodimer can act as a ligand-activated
transcription factor by binding to specific DNA sequences known as ”xenobiotic re-
sponse elements” or ”dioxin response elements” (DREs) [Safe, 2001], [Sogawa et al., 2004],
[Boutros et al., 2004]. The binding to DREs initiates chromatin remodelling and en-
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ables the transcription of a set of target genes the so-called “AhR gene battery”
[Beischlag et al., 2008]. The induced gene products include the xenobiotic-metabolizing
enzymes cytochrome P450 1A1 (CYP1A1), UDP-glucuronosyltransferase (UGT) 1A1 and
aldehyde dehydrogenase 3A1. In addition, the ligand-receptor complex (TCDD/AhR)
can directly interact with proteins of other signalling pathways, such as NF-kappa B
[Tian et al., 1999], the estrogen receptor [Klinge et al., 2000] and the retinoblastoma pro-
tein [Puga et al., 2000] and induce alterations in gene expression without the dimerization
with ARNT and binding to DRE. However, the relevance of these interactions for several
well-known toxic responses to TCDD has been questioned recently [Bunger et al., 2008].
1.1.2 The nongenomic actions of TCDD
During the past few years, evidence has been accumulated that TCDD can also
cause biochemical alterations that are detectable within a few minutes after addition
of the compound to cells in vitro. These effects cannot be explained by the AhR-
mediated gene activation, which is dependent on stimulation of de novo transcrip-
tion and translation. This requires a minimum time of a few hours to become ap-
parent. It has been claimed that the early responses are dependent on a functional
AhR but not ARNT [Matsumura, 2009]. The effects are mainly mediated by rapid
phosphorylation events and are called ”protein phosphorylation pathway” or, more re-
cently ”nongenomic” pathway [Enan and Matsumura, 1995] [Li and Matsumura, 2008],
[Dong and Matsumura, 2008]. These terms were coined to discriminate the ”early ef-
fects” from the classical genomic pathway involving Ahr/ARNT-mediated induction
of gene expression. The term ”nongenomic” was adopted from the field of steroid
receptor signalling which shows marked similarities with respect to the involvement
of both transcription-dependent and -independent activities [Coleman and Smith, 2001],
[Driggers and Segars, 2002].
The rapid increase in intracellular Ca2+ concentration is the most salient ef-
fect of the ”nongenomic” pathway induced by TCDD and has been consistently
demonstrated in organ cultures of TCDD-exposed animals [Canga et al., 1988], pri-
mary cell cultures [McConkey et al., 1988] and mammalian cell lines [Puga et al., 1992],
[Monteiro et al., 2008]. The increase in intracellular calcium takes place within a
few minutes after TCDD exposure and has been suggested to constitute the trig-
ger of the nongenomic action of TCDD [Matsumura, 2009]. In certain cell lines the
ubiquitous Ca2+-dependent cytosolic phospholipase A2 (cPLA2) gets activated upon
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the influx of Ca2+, which cleaves arachidonic acid (AA) from glycerophospholipids
[Dong and Matsumura, 2008], [Li and Matsumura, 2008], [Clark et al., 1991]. Further-
more, cPLA2 activation can also be effected via simultaneous phosphorylation at two
serine residues (Ser505/727). In MCF10A cells [Dong and Matsumura, 2008] and the hu-
man U937 macrophage cell line [Sciullo et al., 2009], TCDD-induced cPLA2 activation was
demonstrated by the stimulation of both Ser505 phosphorylation and AA release. Ser505
phosphorylation has been reported to be caused by the mitogen-activated protein kinase
p38 [Börsch-Haubold et al., 1997], [Börsch-Haubold et al., 1998], [Hefner et al., 2000], but
the possible involvement of p38 in cPLA2 activation in MCF10A cells or U937 cells was not
investigated. The activation of the Src kinase by the formed AA is another early effect medi-
ated by TCDD. In MCF10A cells, the activation occurs within 30 min [Mazina et al., 2004],
[Dong and Matsumura, 2008]. Src activation has been tentatively explained by the ob-
served ability of AA to cause the association of the c-Src homology 2 (SH2) domain with
the EGF receptor (EGFR) at the plasma membrane. This results in an increased EGFR
tyrosine phosphorylation and ERK signalling [Alexander et al., 2006]. In support of the
physiological relevance of these observations, c-src knockout mice were reported to be less
sensitive to toxic endpoints related to the classical “wasting syndrome”, i.e. TCDD-induced
cachexia, than their wild-type counterparts [Dunlap et al., 2002].
It has been suggested [Dong and Matsumura, 2008] that the fundamental aspects of
the nongenomic pathway, i.e. the AhR (but not ARNT) –dependent initial stimula-
tion of Ca2+ entry and the subsequent activation of cPLA2 and Src kinase, which oc-
cur within 15-30 min, are likely to be applicable to most cell types, although details of
the phosphorylation-mediated pathways may vary between different types of cells. More-
over, evidence has been presented that several of the nongenomic actions of TCDD may
be subsequently converted into genomic messages [Matsumura, 2009]. These include,
for example, the activation of the inducible cyclooxygenase isoform, cyclooxygenase-2
(COX-2) [Kraemer et al., 1996], [Puga et al., 1997], [Yang and Bleich, 2004] and, in U937
macrophages [Sciullo et al., 2009], the subsequent transcriptional induction of tumor necro-
sis factor α and interleukin 8, cytokines involved in inflammatory responses.
Recently, a novel branch of the nongenomic pathway linking the TCDD-induced
rapid elevation of intracellular Ca2+ concentration to the upregulation of AhR tar-
get genes, i.e. the genomic response, via phosphorylation events has been identified
[Le Ferrec et al., 2002], [N’Diaye et al., 2006],[Monteiro et al., 2008]. For MCF 7 cells it
was shown that the increase in intracellular Ca2+ concentration results in a transient activa-
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tion of the ubiquitous calcium/calmodulin (CaM)-dependent protein kinase Iα (CaMKIα).
CaMKIα turned out to be a prerequisite for the TCDD-triggered nuclear import of the
ligand-activated AhR and promoter activation of AhR target genes. Confirmatory data
were presented for primary human macrophages [Monteiro et al., 2008]. Evidence was ob-
tained that exposure to TCDD was accompanied by an increased Thr177 phosphorylation
of CaMKIα which has been associated with full CaMKIα activation [Haribabu et al., 1995].
However, a role of the Ca2+/calmodulin-dependent protein kinase kinase (CaMKK) α or
β in this phosphorylation could be excluded, and the protein kinase mediating CaMKIα
activation remained unclear [Monteiro et al., 2008].
1.2 Phosphoproteomics
The proteome is the entire complement of proteins expressed by any given genome, cell,
tissue or organism at a given time under strictly defined conditions [Wasinger et al., 1995]
[Wilkins et al., 1996] and the phosphoproteome is the entirety of the phosphorylated pro-
teins of a given proteome [Larsen et al., 2001], [Kalume et al., 2003]. The phosphorylation
of proteins is a reversible post-translational modification that plays a crucial role in almost
every biological process, like cellular growth, cell division, apoptosis and signalling. Protein
phosphorylation can act as a switch to turn protein activity on or off [Hunter, 1995] and its
dysregulation is known to result in many different human diseases including cancer, immune
diseases and diabetes [Tao et al., 2005]. The process of phosphorylation and dephospho-
rylation is regulated by two groups of enzymes, the kinases and the phosphatases. The
kinases transfer γ-phosphate from ATP to the target protein, while phosphatases remove
the phosphate group from the protein. For the human proteome, approximately 100.000
phosphorylation sites have been estimated [Zhang et al., 2002], but a complete characteri-
zation of all phosphorylation sites in a proteome is still far away. Different amino acids can
be phosphorylated, and the phosphorylation reactions can be divided into four different
groups [Reinders and Sickmann, 2005]. The first class comprises O-phosphorylation which
mostly occurs on serine, threonine and tyrosine residues and which plays the most impor-
tant role in eukaryotes. N -phosphorylation, the second class, occurs on histidine and lysine
residues. Cysteine phosphorylation belongs to the group of S -phosphorylations, the third
group. The final group consists of acyl phosphorylations on aspartic and glutamic acid
residues [Hohenester et al., 2010]. N -, S - and acyl phosphorylations are very labile under
acidic conditions and are particularly difficult to detect [Kowalewska et al., 2010]. In the
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present study, only protein phosphorylation at serine, threonine and tyrosine residues was
analysed.
1.2.1 Phosphopeptide enrichment strategies
For the identification of phosphopeptides, a prior enrichment step is necessary to re-
duce the sample complexity by removing unphosphorylated peptides and to increase
the relative concentration of the phosphopeptides in the sample. Different methods for
enrichment of phosphoproteins and phosphorylated peptides have been recently devel-
oped. The majority of them are affinity-based approaches, like immobilized metal affinity
chromatography (IMAC) [Neville et al., 1997] or titanium dioxide chromatography (TiO2)
[Pinkse et al., 2004]. These methods are widely used due to their high efficiency for the
enrichment of phosphorylated peptides. Other techniques have been developed for the spe-
cific enrichment of phosphopeptides, such as chemical derivatisation using β-elimination
[McLachlin and Chait, 2003]. This method is considered more difficult to handle and shows
a reduced enrichment efficiency. An overview of the most important enrichment strategies
is shown in Figure 1.1. For the present work, phosphorylated peptides were enriched using
a modified IMAC strategy combined with TiO2 chromatography. In the following, both
methods will be described in more detail.
Immobilized metal affinity chromatography - IMAC
IMAC is a widely used method for the enrichment of phosphoproteins and phosphory-
lated peptides. The most common metal ions used for IMAC are Fe3+, Ga3+, Al3+
or Zr4+ which are bound to a stationary phase with the help of chelating complexes
with nitrilotriacetic acid (NTA) or iminodiacetic acid (IDA) [Andersson et al., 1987],
[Posewitz and Tempst, 1999]. Phosphopeptides bind to the metal ions with their nega-
tively charged phosphoryl group through electrostatic interactions [Tsai et al., 2008]. The
phosphopeptides can be eluted from the resin by an increasing pH gradient. A draw-
back of IMAC is the tendency of very acidic peptides to also bind the IMAC resin
[Stensballe et al., 2001]. Peptides containing several aspartic acid or glutamic acid residues
co-purify with the phosphopeptides due to the negatively charged carboxyl groups. This
reduces the specificity and efficiency of IMAC and interferes with the subsequent MS analy-
sis because of the better ionization of non-phosphorylated in comparison to phosphorylated
peptides [Rogers and Foster, 2009]. An esterification of the acidic side chains of aspartate
5
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and glutamate residues prior to IMAC reduces their unspecific binding and increases the
phosphopeptide enrichment efficiency [Ficarro et al., 2002], [He et al., 2004]. However, O-
methyl esterification also increases sample complexity. Another possibility is to increase
the specificity of IMAC by pH adjustment, as the pKa of carboxyl groups is slightly higher
than that of phosphate groups. For sample loading, the pH should be adjusted to around
2.7, since the carboxyl groups of the acidic amino acid residues are already protonated,
whereas the phosphate groups still carry a negative charge and can interact with the IMAC
stationary phase [Kokubu et al., 2005].
Titanium dioxide chromatography - TiO2
Titanium dioxide chromatography is another common method for the enrichment of phos-
phopeptides. Ikeguchi and Nakamura (1997) showed that organic phosphates effectively
bind titanium spheres in acidic conditions and can be subsequently eluted under basic
conditions. However, under the acidic conditions during loading, peptides with several as-
partic and glutamic acids are retained on the TiO2 material resulting in the same problems
associated with IMAC. To overcome this problem, Larsen et al. (2005) added dihydroxy
benzoic acid (DHB) to the loading solution. DHB is a competitive binder which suppresses
the interaction of the acidic peptides with the TiO2 material without inhibiting binding
of the phosphopeptides. However, DHB excessively binds to reversed phase (RP) mate-
rial which results in problems for LC-MS/MS applications using RP columns. A later
study showed that other organic acids, like phthalic acid or glycolic acid, have the same
suppression effects for the acidic peptides as DHB, but do not interfere with LC-MS/MS
[Jensen and Larsen, 2007].
TiO2 is extremely tolerant to buffers and salts which makes the method convenient and
easy to implement in the laboratory.
Sequential elution from IMAC - SIMAC
For the enrichment of phosphopepties, IMAC and TiO2 chromatography were considered
the best methods available. With TiO2 mainly mono-phosphorylated peptides are identi-
fied, whereas IMAC has a preference for multiply phosphorylated ones. In 2008, Thingholm
et al. suggested a strategy called SIMAC (sequential elution from IMAC) which over-
comes the drawbacks of IMAC and TiO2 chromatography. With this strategy, mono-
and multi-phosphorylated peptides from complex samples are enriched in separate frac-
tions. For SIMAC, the crude peptide mixture is first loaded onto the IMAC resin. The
7
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mono-phosphorylated peptides are subsequently eluted from the IMAC material under
acidic conditions and the multi-phosphorylated peptides eluted with basic conditions. The
IMAC flow-through and the mono-phosphorylated fraction are collected separately and
further enriched with TiO2 (Figure 1.1). The three fractions are subsequently analysed by
LC-MS/MS.
1.2.2 Shotgun proteomics
Shotgun proteomics identifies proteins in complex mixtures from tandem mass spectra
of their proteolytic peptides [Marcotte, 2007]. In a typical workflow, the peptides are
fractionated by LC-MS/MS to reduce sample complexity and peptides are introduced into
a tandem mass spectrometer for analysis. The analysis can yield information on both
peptide sequence and the existence of posttranslational modifications. From the peptide
sequences, the proteins originally present in the sample can be identified.
Analysing peptides with a mass spectrometer consists of three different essential steps.
The first is the ionization of the peptides in the ionization source which converts them
into gas-phase ions. At the second stage, the ions are separated by their individual m/z
(mass-to-charge ratio) values in the mass analyser. The last step is the detection of the
ions by the ion detector [Yates, 2000]. For the identification of the peptide, the determined
mass of the unknown molecule is searched against a database which contains the theoretical
masses of the peptides from the relevant species ([McCormack et al., 1997]).
Two peptide ionization methods for proteome applications are available, matrix-assisted
laser desorption ionization (MALDI) [Karas and Hillenkamp, 1988] and electrospray ion-
ization (ESI) [Fenn et al., 1989]. Both ionization methods are capable of generating intact
gas-phase ions from non-volatile and thermally labile molecules, like proteins and peptides
[Chapman, 1996]. MALDI generates gas-phase ions from peptides embedded in a crys-
talline matrix with laser pulses and is preferentially used for samples with low complexity.
ESI, on the other hand, generates the ions from liquid samples and is therefore easy to
combine with liquid chromatography [Wilm et al., 1996]. In addition, it allows a cleaning
of the sample, if required, prior to ionization. During ionization, mainly multiply charged
proteins or peptides are generated in ESI.
Common mass analysers used in phosphoproteomics research are ion traps and
quadrupoles. The quadrupoles consist of four rods, and the different ions are separated by
varying the electric field applied to the rods. The ion traps, on the other hand, capture
all ions and scan them out from low to high m/z by changing the applied radio frequency
8
1.2. PHOSPHOPROTEOMICS
(rf) potential. Since 2005, the Orbitrap mass analyser has been available. Orbitraps have
a high resolving power (up to 100.000) and very high mass accuracy (<5 parts per million
(ppm). The combination of the Orbitrap with a linear ion trap for peptide fragmentation
has been highly suitable for the identification of phosphorylated peptides. In the present
study, the tandem mass spectra were obtained using an LTQ-Orbitrap. The masses of
the intact peptides are obtained in the Orbitrap and the subsequent fragmentation of the
individual peptides is performed in the LTQ (linear ion trap).
Fragmentation of peptides
To retrieve structural information on the peptide level using MS, the peptide needs to
be isolated and fragmented based on the amino acid. The resulting m/z ratios of these
fragments are determined by the mass spectrometer and can then be compared to the the-
oretical fragment spectra of peptides in the peptide database. The acquired fragmentation
spectrum is known as a MS2 (MS/MS) spectrum. If the sequence of the protein is not
known, the obtained sequence information can be searched against homologous protein
sequences in a database using BLAST.
For the fragmentation of peptides, a MS scan of the sample is first performed. In the
next step, in order of decreasing intensity, peptides are isolated in the mass spectrome-
ter based on their m/z ratios and fragmented through the transfer of extra energy to the
peptides. There are several ways to supply the additional energy for fragmentation. The
most common method is termed collision-induced dissociation (CID), where the peptide
of interest is isolated in a collision cell and mixed with an inert gas (Ar, He, N). Colli-
sion of the peptide with the gas converts some of the kinetic energy of the peptide into
vibrational energy [Biemann, 1988]. As a result, the peptide mainly breaks at the peptide
backbone between the carboxy carbon and the amide nitrogen. The fragment ions are
termed daughter ions, the peptide ion is called precursor or parent ion. The daughter ions
are then separated in a second mass analyser and measured by a detector.
The nomenclature of the generated fragment ions depends on the position of the back-
bone cleavage and whether the charge is retained at the N-terminus or C-terminus of the
peptide [Roepstorff and Fohlman, 1984]. In general, the cleavage of the peptide backbone
can occur at three different positions. The break of the Cα-C bond generates a and x ions,
fragmentation of the C-N bond b and y ions and of the N-Cα bond c and z ions. Fragments
will only be detected if they carry at least one positive charge. If the positive charge occurs
on the N-terminus after fragmentation, the fragment ions are termed an, bn or cn, where
9
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n indicates the position of the fragment amino acid counted from the N-terminus. If the
charge is retained on the C-terminal fragment, the ions are called xn, yn or zn.
Figure 1.2: Common nomenclature for peptide fragmentation. Shown is the com-
mon nomenclature for the fragment peptide ions generated by MS/MS. The nomenclature
was originally proposed by Roepstorff and Fohlman [1984] and modified four years later
by Biemann [1988].
An overview of the fragmentation nomenclature is shown in Figure 1.2. For CID frag-
mentation, primarily y and b ions are obtained. A detailed illustration of this fragmentation
is shown in Figure 1.3.
For the identification of phosphopeptides, conventional CID is not sufficient. Phospho-
rylations on serine and threonine residues are highly labile, and with CID fragmentation,
the MS/MS spectra predominantly show the precursor ion at a lower m/z corresponding
to a loss of the phosphoric acid group (neutral loss of 98 Da). A sufficient fragmentation of
this phosphorylated peptide can be obtained through selecting the fragment ion originating
from the loss of the phosphoric acid group for a second round of fragmentation, which is
termed phosphorylation-directed MS3 [Beausoleil et al., 2004]. This method yields more
detailed sequence infomation and can indicate the specific phosphorylation site on the ser-
ine or threonine residue. Recently, a new variation of the MS3 method was developed,
termed multi-stage activation (MSA) [Schroeder et al., 2004]. For MSA, the MS2 and the
MS3 scan are combined in a hybrid MS/MS spectrum with the sequence information de-
rived from fragmentation of the precursor after neutral loss and original fragmentation.
This technique is faster than the MS3, but MSA is limited to ion traps. For the present
study, MSA type fragmentation was used.
10
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Figure 1.3: Schematic representation of the CID fragmentation.
1.2.3 Quantitative phosphoproteomics
Quantitative phosphoproteomics is the relative quantitation of the phosphoproteins or
phosphopeptides from two or more samples, such as cultured cells treated with a
test agent and untreated cells. This quantitative approach can be differentiated into
three different types: metabolic labelling, chemical labelling and label-free approach
[Palmisano and Thingholm, 2010]. For metabolic and chemical labelling, a stable isotope
is used to tag the protein or peptide, but the point in the workflow where the isotope is
incorporated differs, depending on the particular method chosen. For metabolic labelling,
the labels are introduced into live cells through the culture medium. For chemical la-
belling, the label is introduced at some downstream stage during sample processing. For
both methods, the same proteins or peptides from the control cells can be distinguished
from those treated during MS analysis because of the different masses of the isotopes. For
the label-free approach, no label is introduced into the samples. Here, the quantitation is
based on the liquid chromatography, MS or the MS/MS data. For the present study, a
metabolic labelling approach, the stable isotope labelling with amino acids in cell culture
(SILAC), was used.
SILAC was introduced in 2002 by two different groups and is based on the incorpo-
ration of isotopically labelled amino acids into growing cells in culture [Zhu et al., 2002],
[Ong et al., 2002]. The labelled amino acids will be incorporated into the proteins, and
after several cell cycles, certain amino acids will be nearly completely exchanged by the
labelled ones. As a result, the labelled peptides are heavier than the peptides containing
the natural amino acid. The cells are then lysed and combined with the cells grown in
normal medium. During MS analysis, the labelled and unlabelled peptides appear together
and can be quantified by comparing their relative signal intensities. The most common
11
CHAPTER 1. INTRODUCTION
amino acids for the SILAC approach are lysine and arginine, where the carbon atom is
exchanged with 13C and/or the nitrogen atom with 15N. Both isotopes have no influence on
the chemical behaviour of the peptides during the subsequent phosphopeptide enrichment
step and the liquid chromatography step prior to MS analysis.
SILAC is a straightforward method and has already successfully been used for
the study of phosphorylation changes under different conditions [Gruhler et al., 2005],
[Olsen et al., 2006], [Malik et al., 2009]. The early introduction of the label into the sam-
ples reduces the risk of variations in sample handling during sample processing and, thus,
the generation of erroneous quantitative results.
1.3 The aim of the present study
Whereas the genomic response to TCDD has been analysed in several large-scale studies
at the level of the transcriptome and the proteome both in vitro and in vivo, a systematic
study of the proteins involved in the early nongenomic action of TCDD has not been
performed previously. Therefore, the present study was conducted with the aim to identify
TCDD-induced alterations in protein phosphorylation occurring early after the onset of
TCDD exposure in order to shed light on the alterations in signal transduction potentially
involved in the early, nongenomic effects of TCDD.
In the present study, the rat hepatoma cell line 5L was used as a model
system. This cell line is a descendant of the H-4-II-E cell line established by
[Pitot et al., 1964] from the Reuber H35 rat hepatoma [Reuber, 1961]. 5L cells are
epithelial-like cells which express both the AhR and the ARNT protein and which
are highly responsive to TCDD-induced gene activation. They have been previ-
ously used in a variety of studies dealing with the role of AhR in cell cycle
regulation and TCDD toxicity [Göttlicher et al., 1990], [Göttlicher and Wiebel, 1991],
[Wiebel et al., 1991], [Weiss et al., 1996], [Ge and Elferink, 1998], [Reiners et al., 1999],
[Elferink et al., 2001], [Levine-Fridman et al., 2004]. With respect to nongenomic actions
of TCDD in this cell line, Weiss et al. (2005) observed that TCDD exposure of the cells
is associated with the rapid phosphorylation of the p38 mitogen-activated protein kinase
(MAPK) in an AhR-dependent, but, importantly, transcription-independent manner. p38
activation was observed as early as 1 h after addition of TCDD and resulted in subsequent
transcriptional induction of the proto-oncogene c-jun. Phosphorylation of p38 was not
effected by any of the kinases known to phosphorylate p38, suggesting a novel cross-talk
12
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between AhR and MAPK signalling. The signalling pathway resulting in p38 phosphory-
lation and the kinase involved remained unclear.
In the present quantitative phosphoproteomic analysis of the effects of TCDD in 5L
cells, short exposure periods of 0.5, 1 and 2 hours were used, i.e. treatments that were un-
likely to result in significant alterations in the abundance of proteins with TCDD-regulated
expression which requires some time due to its dependence on de novo transcription and
translation. The study was performed with the expectation to uncover proteins previ-
ously unknown to exhibit rapid alterations in phosphorylation as a consequence of TCDD
exposure and which might give clues to pathways involved in nongenomic signalling pre-
ceding alterations in gene expression. Moreover, it was anticipated to identify proteins
with altered phosphorylation as a consequence of their involvement in the regulation of
transcription induced by the DRE-bound liganded AhR/ARNT heterodimer. And, finally,
the study was expected to provide novel information on the global phosphoproteome of rat
cells with respect to the identification of novel phosphorylation sites of phosphoproteins
and the discovery of proteins previously not known to be phosphorylated.
13
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Chapter 2
Material and methods
2.1 Materials
RPMI 1640 without arginine and lysine, PBS and dialysed fetal calf serum were from Gibco-
Invitrogen (Carlsbad, CA). U-13C6-L-lysine hydrochloride and U-
13C6
15N4-L-arginine hy-
drochloride were from Invitrogen (Carlsbad, CA, USA). U-15N4-L-arginine hydrochloride
was from Cambridge Isotope Laboratories (Andover, MA, USA) and TCDD (purity >
99%) in dimethyl sulfoxide was from Ökometric (Bayreuth, Germany). Benzonase, KN-
92, KN-93 and W-7 were from Merck (Darmstadt, Germany). Arginine, lysine, Tris,
MgCl2, NaCl, phosphatase inhibitor cocktails 1 and 2, acetonitrile, formic acid, ethanol,
acetone, PHOS-SelectTM Iron Affinity Gel, 2-APB, BAPTA-AM, besylate, Diltiazem hy-
drochloride, Nifedipine, sodium orthovanadate and Triton X-100 were from Sigma-Aldrich
(Taufkirchen, Germany). ”Complete” protease inhibitor cocktail tablets were from Roche
(Mannheim, Germany). Sequencing grade modified trypsin was from Promega (Madison,
WI, USA). Lys-C was from Wako (Richmond, VA, USA). Hydrogen peroxide was pur-
chased from J.T. Baker (Deventer, Netherlands). TSKGel Amide-80 5µm HILIC 2 mm
column was from Tosoh Bioscience (Stuttgart, Germany). Poros Oligo R3 RP material
was from PerSeptive Biosystems (Framingham, MA, USA). GELoader tips were from Ep-
pendorff (Hamburg, Germany). Glycolic acid and trifluoroacetic acid were from Fluka
(St. Louis, MO, USA). 3M Empore C8 disks were from 3M Bioanalytical Technologies
(St. Paul, MN, USA). Syringe for HPLC loading was from SGE (Victoria, Australia).
The water was from an Elga Purelab Ultra (Bucks, UK). Titanium dioxide beads were
from GL Sciences Inc. (Tokyo, Japan). ReproSil-Pur C18 AQ, 5µm was from D. Maisch
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(Ammerbuch-Entringen, Germany). PicoTipTMemitter needles were from New Objective,
DNU - Nowak Umweltanalysen (Berlin, Germany).
2.1.1 Software
The mass spectrometry raw files generated by the LTQ Orbitrap XL mass spectrometer
were inspected with the software Xcalibur 2.1 (Thermo Fisher Scientific, Bremen, Ger-
many). MALDI spectra were analysed using the program flexAnalysis (Bruker Daltonics,
Bremen, Germany). MSQuant (University of Southern Denmark, Odense, Denmark) was
used for the quantitation and phosphosite localization scoring of the identified phospho-
peptides. The program ”R” (Version 2.9.1), a statistical data analysis software freely
available under: http://cran.r-project.org, was used for the statistical analysis. For this
work, the following R-Packages were dowloaded and used: limma, q-value, BioIDmapper
and biomaRt.
Protein Center (http://www.proxeon.com; Proxeon, Odense, Denmark) is a consoli-
dated protein database. The software was used for the annotation of proteins to databases
like Pfam or Gene Ontology to support the interpretation of the experimental data.
2.2 Methods
2.2.1 Cell culture
5L Rat hepatoma cells
5L cells were cultured as monolayers in RPMI 1640 medium supplemented with 10% fetal
bovine serum, 100 µg/ml streptomycin and 100 U/ml penicillin at 37 ◦C in a humidified
atmosphere containing 5% CO2.
SILAC labelling
For stable isotope labelling of the 5L cells, normal lysine (Lys0), 13C6-lysine (Lys6),
15N4-
arginine (Arg4) and 13C6
15N4-arginine (Arg10) were used. The amino acids were dissolved
in RPMI medium without arginine and lysine supplemented with 10% dialysed fetal bovine
serum, 100µg/ml streptomycin and 100 U/ml penicillin. For the ”light” condition, the
medium was supplemented with Lys0 and Arg4 and for the ”heavy” condition with Lys6
16
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and Arg10 according to the labelling scheme of van Hoof et al. [Van Hoof et al., 2007].
The concentrations of arginine and lysine were 75 mg/L.
Arginine and lysine are the most common amino acids for labelling. This is due to the
use of the protease trypsin in the majority of proteomic experiments. Trypsin cleaves at
the carboxy termini of arginine and lysine residues. Thus, when these amino acids are used
for labelling, every tryptic peptide is labelled except for the C-terminal one.
The cells were grown for at least seven cell cycles (about seven days) with periodical
splitting when they reached a density of around 1 ∗ 107 cells/10-cm dish.
TCDD treatment
During the final 16 hours before the start of the TCDD exposure, the cells were starved
in labelling medium without serum. The ”heavy” cells were treated with 1 nM TCDD
dissolved in Me2SO and the ”light” cells with Me2SO alone as a control for 0.5, 1 or 2
hours.
Preparation of sodium pervanadate
To produce the protein tyrosine phosphatase inhibitor pervanadate, 100 mM sodium or-
thovanadate solution was prepared and the pH adjusted to 10 with 1 M HCl. Due to the
basic pH the solution became yellow. After another boiling step, the solution became clear
again. The pH was again adjusted to 10 when the sodium orthovanadate solution reached
room temperature. The boiling and cooling steps were repeated until the pH was stable at
pH 10.0 and the solution remained clear. Directly before use, the prepared 100 mM sodium
orthovanadate solution was mixed 1:1 (vol/vol) with a 0.36% hydrogen peroxide solution
to generate a 50 mM sodium pervanadate solution.
Cell lysis
Following cellular exposure, the medium was removed and cells were washed twice with
10 ml ice cold PBS. Then 1.5 ml of lysis buffer containing 1µl/ml Benzonase, 1 mM MgCl2,
25 mM Tris-HCl, pH 7.4, 120 mM NaCl, 1% Triton X-100, protease inhibitors (one ”com-
plete” protease inhibitor cocktail tablet per 50 ml), phosphatase inhibitor cocktails 1 and 2
(0.5 ml each per 50 ml) and 1 mM sodium pervanadate was added to each 10 -cm dish. The
lysates were transferred to Eppendorf tubes, shaken for 30 min at 4 ◦C and centrifuged at
15.000 g for 10 min at 4 ◦C. The protein concentrations of the supernatants from the ”light”
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and the ”heavy” cells were determined with the Bradford assay and mixed 1:1. The pellets
were discarded.
2.2.2 Sample preparation
Acetone/ethanol precipitation
The proteins were precipitated by adding four volumes of ice cold ethanol. After 15 min
incubation, four volumes of ice cold acetone were added and the mixture was incubated at
-20 ◦C overnight. The precipitated proteins were centrifuged at 15.000 g for 20 min at 4 ◦C.
The pellet was washed three times with 2:2:1 ethanol/acetone/water.
Proteolysis
The precipitated proteins were dissolved in 6 M urea, 2 M thiourea and 50 mM NH4HCO3.
The proteins were reduced for 2 h at 30 ◦C with 20 mM DTT and then alkylated with 40 mM
iodoacetamide for 45 min in the dark at room temperature. Then they were digested with
endoproteinase Lys-C (1:100 enzyme to protein ratio) for 3 hours. For digestion with
trypsin (1:50 enzyme to protein ratio), the proteins were diluted in 50 mM NH4HCO3 to a
urea concentration of 1 M and incubated with trypsin at 30 ◦C for 16 h. The digestion was
quenched by adding trifluoroacetic acid (TFA) to reach a pH of <3.
Sequential elution from IMAC - SIMAC
PHOS-SelectTM Iron Affinity Gel beads were washed twice with 0.1% TFA and once with
50% ACN, 0,1% TFA (loading buffer) to remove the glycerol. Finally, the beads were
resuspended in loading buffer and the sample was added. For 200µg of peptides, ap-
proximately 50µl PHOS-SelectTM Iron Affinity Gel beads were used. After incubation by
end-over-end rotation for 1 h, the peptide-bead mixture was transferred to a constricted
gel loader tip. The flow-through and the first wash with loading buffer (100µl) were col-
lected. The mono-phosphorylated peptides were eluted with 20% ACN, 1% TFA (100µl)
and again collected. Both fractions were combined and dried down in a vacuum centrifuge.
The multi-phosphorylated peptides were eluted with 1% NH4OH (70µl) and acidified with
formic acid (FA) to obtain a final FA concentration of 1%. The multi-phosphorylated
peptides were desalted using Poros R3 P10 micro columns and analysed by LC MS/MS.
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Hydrophilic interaction chromatography - HILIC
The mono-phosphorylated peptides from the SIMAC enrichment were fractionated by hy-
drophilic interaction chromatography (HILIC). The dried SIMAC fraction was resuspended
in B-solvent (80% ACN, 0.1% TFA) and loaded onto a 2 mm TSKGel Amide-80 HILIC
column connected to an Äkta Basic FPLC system.
Loading was performed in B-solvent at a flow rate of 200µl/min for 12 min. The
peptides were separated by an inverse gradient (100% - 70% B-solvent within 28 min and
70% - 0% B-solvent within 5 min) with an increasing amount of A-solvent (0.1% TFA) at
a flow rate of 200µl/min. A total of 16 fractions were collected, as shown in Table 2.1.
The fractions were dried down in a vacuum centrifuge.
HILIC fraction Part of the gradient Fraction time
1 Sample loading 15 min
2 Gradient 1 - 5 min 5 min
3 Gradient 6 - 9 min 4 min
4 Gradient 10 - 12 min 3 min
5 Gradient 13 min 1 min
6 Gradient 14 min 1 min
7 Gradient 15 min 1 min
8 Gradient 16 min 1 min
9 Gradient 17 min 1 min
10 Gradient 18 min 1 min
11 Gradient 19 min 1 min
12 Gradient 20 min 1 min
13 Gradient 21 - 22 min 2 min
14 Gradient 23 - 24 min 2 min
15 Gradient 25 - 28 min 4 min
16 End 10 min
Table 2.1: Overview of the collected HILIC fractions
Titanium dioxide chromatography - (TiO2)
To enrich the mainly mono-phosphophorylated peptides, the TiO2 method was used essen-
tially as described by Thinghol et al. (2006). TiO2 beads were washed with water, then
ACN and finally loading buffer (1 M glycolic acid in 80% ACN, 5% TFA). For every 200µg
of peptides around 0.6 mg TiO2 particles were used. Each HILIC fraction was dissolved
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in 5µl 1% SDS, 200µl loading buffer, and the appropriate amount of TiO2 added. The
peptides and TiO2 resin were incubated for 15 min under vigorous shaking before the beads
were spun down by centrifugation at 2000 g for 30 s. The supernatant was collected in a
fresh tube and the TiO2 beads were washed with loading buffer, followed by 80% ACN/
5% TFA, then 30% ACN/ 0,1% TFA and by distilled water. Phosphopeptides were eluted
from the beads with 50µl 1% NH4OH using an incubation time of 10 min under vigorous
shaking. The supernatant was acidified with 5µl FA. The phosphopeptides were desalted
using Poros R3 P10 micro columns and analysed by LC-MS/MS. The collected supernatant
from the first TiO2 incubation with loading buffer was again treated with TiO2 as described
above.
Comparison of the SIMAC and TiO2 method
In order to compare the performance of the SIMAC and TiO2 method when used alone,
they were tested with a tryptically digested 12-protein-mixture (Protein Research Group,
University of Southern Denmark, Odense, DK). Each protein was dissolved in 50 mM
NH4HCO3 and reduced and alkylated in 10 mM DTT and 20 mM iodoacetamide. The
proteins were digested with trypsin (1/50 w/w) overnight and the reaction quenched with
TFA. The phosphorylated peptides were then enriched using the SIMAC or TiO2 method
as described above.
StageTip purification
Peptides were purified using StageTips. StageTips were prepared by stamping out a small
plug of a 3M Empore C8 disk and depositing at the end of a P10 tip. Poros R3 material in
ACN was packed in the pipette tip on top of the C8 disk. The microcolumn was washed
with ACN and equilibrated with 0.1% TFA. Phosphopeptide samples were loaded onto the
columns using a 1 ml disposable syringe. The columns were washed once with 0.1% TFA
and the peptides eluted with 50% ACN and 0.1% TFA. Samples were nearly dried down in
a vacuum centrifuge and redissolved in 0.5µl 100% FA and an additional 4.5µl 0.1% FA
for analysis by LC MS/MS.
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2.2.3 Mass spectrometric methods
MALDI MS
To evaluate the success of the phosphopeptide enrichment methods SIMAC and TiO2, the
samples obtained from the tryptic digestion of the 12-protein-mixture and the subsequent
enrichment were analysed on a Bruker Ultraflex mass spectrometer (Bruker Daltonics,
Bremen, Germany). All spectra were acquired in positive reflector ion mode. The samples
were spotted on a MALDI target together with DHB (20 mg/ml) in 70% ACN/ 0.1% TFA/
1% phosphoric acid. The spectra were processed using the flexAnalysis software (Bruker
Daltonics, Bremen, Germany).
LC MS/MS
The enriched and purified phosphopeptides were analysed on an LTQ Orbitrap XL Mass
Spectrometer (Thermo Fischer Scientific, Bremen, Germany). The samples were applied
onto an EASY nano-HPLC system (Proxeon Biosystems, Odense, Denmark) comprising
a self-packed 16 -cm analytical column (100µm I.D., 360µm O.D., ReproSil-Pur C18 AQ
3µm). The peptides were loaded with a flow rate of 550 nl/min in 0.1% FA (solvent A)
and eluted at a flow rate of 250 nl/min with a gradient from 100% solvent A to 34%
solvent B (95% ACN/ 0.1% FA). The length of the gradient depended on the complexity
of the sample. Three different gradients were used: 100 min, 50 min and 30 min. The
nano-HPLC system was connected online to the mass spectrometer with a nano ES ion
source and PicoTipTM emitter needles. The mass spectrometer was operated in positive
ion mode and a data-dependent acquisition method that automatically switched between
MS and MS/MS was employed. Each MS scan was followed by up to 5 MS/MS scans.
The full scan was acquired in the Orbitrap with an automatic gain control (AGC) target
value of 1 * 106 ions and a maximum fill time of 500 ms. The ion resolution was set to
R = 60000 at 400 m/z. The top five most intense ions were selected for fragmentation
in the LTQ. Fragmentation was induced by collision-induced dissociation. For the LTQ,
the AGC target value was set to 30000 ions and a maximum fill time of 300 ms. For an
improved fragmentation of phosphopeptides, the MSA algorithm was employed if a MS/MS
spectrum showed a loss of phosphoric acid from the parent ion (neutral loss of 97.97, 48.99,
or 32.66 Thomson (Da)). Ions selected for MS/MS were dynamically excluded from further
fragmentation for a duration of 45 s.
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2.2.4 Bioinformatics and biostatistics analysis
Database searching
The acquired MSn spectra were converted into Mascot generic format (mgf) using the
software DTASuperCharge, version 1.37 (http://msquant.sourceforge.net/). De-isotoping
was performed using the default settings from DTASuperCharge. The processed spectra
were searched against the rat IPI protein database version 3.60 which contains 39863
protein sequences. The search was performed using an in-house Mascot database search
program (version 2.2) with carbamidomethyl (C) as a fixed modification and acetylation
(protein N-terminal), oxidation (M), phoshphorylation (ST and Y) and the SILAC labelling
(K-6, R-4, R-10) as variable modifications. Trypsin was chosen as the enzyme and up to
two miss-cleavages were allowed. For the parent ion, a mass accuracy of 10 ppm was
used and for the fragment ions a mass accuracy of 0.8 Da was specified. A concatenated
decoy database search was performed derived from the IPI rat database. Proteins with
a false discovery rate (FDR) of ≤ 1% and peptides with an ion score of ≥ 20 (MudPIT)
multidimensional protein identification technology) scoring) were accepted.
Quantitation and phosphosite localization
In general, for a reliable protein identification and subsequent quantitation at
least two different peptides must be identified. However, the different phospho-
rylation sites on a given protein can be differentially regulated [Olsen et al., 2006],
and therefore every identified phosphorylated peptide must be quantitated individu-
ally [de la Fuente van Bentem et al., 2008]. Quantitation of phosphopeptides and non-
phosphorylated peptides was performed using the software MSQuant version 1.0a70.
MSQuant quantifies the peptides based on the first isotopic peak of the isotopically la-
belled peptides by summing up the ion intensities in a specified interval around the centroid
of the peak [Mortensen et al., 2009]. As a measure of the reliability of the phosphoryla-
tion site assignment, a PTM score for every phosphosite was calculated using MSQuant.
The PTM score is a probability-based scoring system for phosphorylation site assignment
[Olsen and Mann, 2004]. Briefly, to calculate the PTM score, the four most intense frag-
ment ions per 100 Da in a MS2 or MS3 spectrum are taken and the matches k with all
possible combinations of b- and y- ions and their phosphorylation sites in a given peptide
sequence are counted. The PTM score is calculated as −10 · log10(p), where p is calculated
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as:
p = (k!/(n!(n− k)!) · pk · (1− p)(n−k)
= (k!/(n!(n− k)!) · 0.04k · 0.96(n−k)
With n as the total number of possible b- and y-ions.
After calculating the PTM score and the regulation factors with MSQuant, every MS
and MS/MS spectrum was manually validated. Peptides with a low signal to noise ratio, ion
score under 20, low number of MS scans and overlapping peaks were removed. The retained
peptide lists from MSQuant were then further processed with the statistical program R to
identify the statistically significantly regulated peptides.
Removal of duplicate peptides and normalisation
Before the statistical test was performed, redundant peptides were removed,where the
peptide with the highest ion score was kept. Furthermore, the occurrence of duplicate
peptide sequences with different IPI accessions was inspected. If one peptide was detected
with different accessions, only the peptide belonging to the IPI identifier with the highest
number of different peptides observed was retained.
Next, a normalisation of the calculated peptide ratios was performed to correct inac-
curacies caused by the sample preparation, i.e. the 1:1 mixing of proteins from the ”light”
and the ”heavy” state. A global normalisation method was used, where the log median of
the peptide ratios was adjusted to zero. The normalisation was performed with the open
source program R. To visualize the normalisation effect, MA plots were generated using R.
Statistical analysis
In the present study, three different, independent biological replicates were analysed for
the datasets obtained for the 30 min and 1 hour exposures to TCDD and two biological
replicates were analysed for the 2 hours dataset.
To assess the conformance of the individual data sets of a time point, Pearson correlation
coefficients ”r” were calculated by R for the peptide ratios from the biological replicates
against the mean of the ratios of the biological replicates. The coefficient r indicates the
degree of linear dependence between two variables and is between -1 and 1. A positive
value stands for a positive association, whereas a negative value implies a negative or
inverse association [Sachs and Hedderich, 2009].
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The ratios of the biological replicates were merged together based on the peptide se-
quence. Only peptides that were found at least twice for a given time point were used
for the following statistical test. The normalised and merged ratios were than fitted to a
linear model and a moderated t-test conducted. The linear modelling and the moderated
t-test were performed using the R-package ”limma”. The resulting p-values were used to
calculate q-values with the R-package ”q-value”. The p-value is a measure for significance
in statistics [Käll et al., 2008] and is a measure of probability of rejecting or accepting the
null hypothesis. A low p-value means a low probability that the null hypothesis is true.
The null hypothesis in this analysis is that no peptides are regulated. The q-value is a
method for the correction of multiple testing, meaning the value is a threshold for the false
discovery rate (FDR, i.e. the null hypothesis was wrongly rejected).
Peptides with a q-value lower than 0.05 were accepted as significantly regulated and
Volcano plots were generated with the limma package.
Annotation
Following the statistical analysis, the data for every time point were mapped to differ-
ent identifiers from different protein databases such as Uniprot, Gene Ontology (GO) or
KEGG using the IPI accession number. The mapping was done using the software R in
combination with the packages BioIDMapper and biomaRt.
Phosphoset analysis
For the global analysis of the enriched phosphorylated peptides, all identified peptides from
the different time points and biological replicates were merged together. The redundant
peptides were removed and saved as an Excel file. Counting of the phosphorylated peptides,
sites and proteins was performed in Microsoft Excel. The identification of known and
hitherto unknown phosphorylation sites was done with an in-house written Perl script.
For this analysis, the Swiss-Prot accession numbers were used and searched against the
UniProt database.
2.2.5 Western blot analysis
For Western blot analysis of the effects of TCDD on the abundance of CYP1A1 and Rdbp
protein, cells were treated and lysed as described above and equal amounts of total protein
(20µg) were resolved on 12% polyacrylamide gels (XCell SureLock, Invitrogen, Darmstadt,
24
2.2. METHODS
Germany). Proteins were transferred on nitrocellulose membranes using the iBlot dry
blotting system (Invitrogen). Membranes were blocked with 3% bovine serum albumin
in TBS/Tween, and CYP1A1 and Rdbp were detected using an anti-CYP1A1 antibody
(G-18, Santa Cruz Biotechnology, Santa Cruz, USA) and an anti-RDBP antibody (AVIVA
Systems Biology, San Diego, USA), respectively, horseradish peroxidase-labelled secondary
antibodies and ECL detection kit (LumiGLO, Cell Signaling Technology, Beverly, USA).
Bands were quantitated by densitometry using the ImageMaster 1D Elite software, v4.00
(Pharmacia Biotech, Uppsala, Sweden). The actin band, which served to normalize for
the amount of protein loaded, was detected using an anti-actin antibody (clone AC-40,
Sigma).
2.2.6 Ethoxyresorufin O-deethylase (EROD) assay
As a measure of the enzymatic activity of cytochrome P4501A1 (CYP1A1) in 5L cells,
the 7-ethoxyresorufin O-deethylase (EROD) activity was determined in whole cell lysates.
The assay determines the conversion of the substrate 7-ethoxyresorufin into the strongly
fluorescent dealkylation product resorufin. The assay was performed according to the
method of Pohl and Fouts (1980) using modifications described by Schwirzer et al. (1998).
Following incubation of the cells with DMSO or TCDD for up to 24 h. They were washed
twice with PBS, pelleted by centrifugation and stored frozen (-20 ◦C) until use. The frozen
pellets were re-suspended in 50 mM Tris-HCl (pH 7.6) to obtain a protein concentration
between 1-2 mg/ml, and 20µl of the cell suspension was added to 230µl of a solution
containing 2µM 7-ethoxyresorufin, 400µM NADPH, 10µM dicumarol, and 5µM MgSO4.
Dicumarol was included to inhibit the enzyme DT-diaphorase which converts resorufin
into a non-fluorescent product. The mixture was incubated in a water bath at 37 ◦C for
30 min in the dark. The reaction was stopped by placement of the mixture in ice water and
addition of 500µl of ice-cold methanol. Following centrifugation in a desktop centrifuge,
300µl of the supernatant were transferred into black 96-well microtiter plates (Nunclon
Delta, Thermo Scientific Nunc, Roskilde, Denmark). The fluorescence of the dealkylation
product resorufin was read in a microplate reader (Synergy 2, BioTek, Vermont, USA)
using an excitation wavelength of 540 nm and an emission wavelength of 620 nm. Each
sample was analyzed in duplicate. The amounts of resorufin formed were calculated using
a calibration curve generated with resorufin standards.
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Results
To detect changes in protein phosphorylation resulting from the treatment of 5L cells with
TCDD, we employed stable isotope labelling in cell culture (SILAC) as a quantitation
method. The SILAC approach is based on the differential metabolic labelling of proteins
from treated and untreated cells at the cell culture level.
The cells designated for the use as control cells were labelled with normal lysine and
15N4-arginine (Arg4), while those designated for TCDD treatment were labelled with
13C6-
lysine (Lys6) and 13C6
15N4-arginine (Arg10). After complete substitution of the normal
amino acids by the heavy analogues, the cells were serum-starved for 16 hours followed
by treatment of the ”light” and ”heavy” cells with DMSO and TCDD, respectively, for
30 minutes, 1 hour and 2 hours. Following cell lysis and determination of the protein con-
centrations, treated and control cells were mixed in a one-to-one ratio. The proteins were
then precipitated and proteolysed with trypsin. The resulting peptides were separated by
hydrophilic interaction chromatography (HILIC) and the fractions enriched for phosphory-
lated peptides using SIMAC and TiO2. Phosphopeptides were analysed by high-resolution
mass spectrometry on a linear ion trap instrument coupled to an Orbitrap (LTQ-Orbitrap).
All data were searched using an in-house MASCOT server. A peptide was accepted
for quantitation when it had a MASCOT ion score of at least 20. The relative quan-
titation of the peptides was performed using MSQuant software [Mortensen et al., 2009]
(http://msquant.sourceforge.net). All peptide spectra were manually validated and pep-
tides with low number of MS scans, low signal/noise ratio or overlapping peaks were
removed and not used for quantitation. As a guide, Figure 3.1 shows the workflow of cell
culture, sample preparation and phosphopeptide analysis.
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Figure 3.1: Workflow illustrating the principal steps of sample preparation and
processing
3.1 SILAC labelling
SILAC is a method for relative quantitation, based on the relative peak intensities of
labelled and unlabelled peptides measured by mass spectrometric analysis. An accurate
protein quantitation requires a near complete substitution of the normal amino acid by the
isotopically labelled (”heavy”) amino acid. Therefore, essential amino acids, i.e. amino
acids that cannot be synthesised by the cell, are generally used for labelling. Lysine is an
essential amino acid and needs to be added to the medium. Arginine, on the other hand,
is a non-essential amino acid in adult vertebrates. However, Scott et al. (2002) showed
that arginine is an essential amino acid for several cell lines. In this study, Scott and
co-workers tested 26 different cell lines and observed that the majority were very sensitive
to arginine deprivation which caused a loss of viability. Since no information was available
on the dependence of the 5L cells on lysine, the non-essential amino acid arginine and the
efficiency of the isotopic labelling, cell proliferation in medium with and without lysine and
arginine was monitored.
A total of 5 ∗ 105 cells each were seeded in 5 -cm dishes in arginine- and lysine- defi-
cient medium supplemented with 10% dialysed fetal calf serum and arginine and lysine
(100 mg/L each), only arginine (100 mg/L) or only lysine (100 mg/L). Microscopic pictures
were taken after 24 h, 48 h and 72 h. The photographs in Figure 3.2 demonstrate a dramatic
change of cell growth and cell morphology in arginine- or lysine-deficient media compared
to those in complete medium. Already after 24 h, cells with arginine or lysine deprivation
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(a) 5L in normal medium, 24 h (b) 5L in Arg-def. medium, 24 h (c) 5L in Lys-def. medium, 24 h
(d) 5L in normal medium, 48 h (e) 5L in Arg-def. medium, 48 h (f) 5L in Lys-def. medium, 48 h
Figure 3.2: Growth of 5L cells cultured in different media for 24 h and 48 h.
Pictures were taken with an inverted optical microscope at a magnification of 32x. The
cells were grown in normal medium (a, d), arginine-deficient medium (b, e) and lysine-
deficient medium (c, f) for 24 h (a, b, c) and 48 h (d, e, f).
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were more slender and less firmly attached to the culture dishes suggesting that they were
stressed. After 48 h, a significant decrease in cell number was observed for these cells,
whereas cells cultured in normal medium were already confluent. After 72 h, nearly all
cells in arginine- or lysine-deficient media were detached from the dishes and undergoing
apoptosis (not shown).
These data show that 5L cells require the provision of the essential amino acid lysine
as well as arginine for cell proliferation and survival. It appears that 5L cells, like various
other cell lines, cannot synthesize arginine in sufficient quantities and both arginine and
lysine must be regarded as essential amino acids for these cells. Arginine and lysine are
therefore suitable amino acids for the stable isotope labelling of proteins of 5L cells.
In order to determine the time required for a complete incorporation of the labelled
amino acids (Arg4, Arg10, Lys6) into the cellular proteins, a time course experiment was
performed. One population of cells was grown in Lys/Arg4 medium and another population
in Lys6/Arg10 medium (100 mg/L concentration for the heavy amino acids). After 1 day,
3, 5 and 7 days samples were lysed, proteins separated using a SDS-PAGE gel, protein
bands were cut out, proteolysed with trypsin and analysed by MALDI MS. As shown in
Figure 3.3, an incorporation of the labelled amino acids of about 50% was observed already
after 24 hours. This finding was consistent with the doubling time of 5L cells of around
24 h observed in our laboratory. An incorporation of around 98% was obtained after five
cell doublings and almost total incorporation after seven doublings.
The similar experiment was used to establish concentrations of the labelled amino acids
optimal for cell growth and sufficient label incorporation. Concentrations of 50 mg/L,
75 mg/L and 100 mg/L medium were tested for Lys6 and Arg10-supplemented media. The
incorporation of the isotope-labelled amino acids was quantified for five different peptides
with C-terminal arginine and lysine residues, respectively. Figure 3.4 clearly shows that
after seven days almost complete incorporation was reached with all three concentrations.
However, whereas for 75 mg/L and 100 mg/L a nearly complete substitution was already
reached after five days, the rate of incorporation was slightly lower for 50 mg/L, suggesting
that this concentration was insufficient to fully support the growth of the cells. Thus,
75 mg/L was chosen as the optimal concentration of arginine and lysine for experiments
involving the quantitation of phosphopeptides from 5L cells.
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Figure 3.3: Incorporation of Lys6- and Arg10-labelled amino acids over time.
MALDI MS spectra for two different peptides after 0 h, 24 h, 72 h and 120 h are shown.
a) SILAC incorporation of 13C6-lysine (Lys6) for the peptide VAPEEHPVLLTEAPLNPK.
b) SILAC incorporation of 13C6
15N4-arginine (Arg10) for the peptide SYELPDGQVIT-
IGNER.
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(a) 5L cells in Arg10 medium (b) 5L cells in Lys6 medium
Figure 3.4: Time and concentration dependence of the incorporation of isotopi-
cally labelled lysine and arginine into 5L cells. The labelled amino acids were (a)
13C6
15N4-arginine and (b)
13C6-lysine. The incorporation was determined 1 day, 2, 3, 5
and 7 days after addition of the labelled amino acid.
3.2 SIMAC for phosphopeptide enrichment
3.2.1 Applying SIMAC to standard peptides
In the present study, a combination of two different affinity-based methods, immobilized
metal affinity chromatography (IMAC) and TiO2 affinity chromatography, was used for
the enrichment of phosphopeptides.
To evaluate the performance of the SIMAC and the TiO2 approach alone, a com-
parison of both methods using a peptide mixture originating from 12 different standard
proteins which included three phosphoproteins (α-casein, β-casein and ovalbumin) was
performed. For the comparison, the proteins were proteolysed with trypsin and mixed in
equal amounts. One pmol of the standard mixture was used for this comparison. Figure 3.5
shows a MALDI spectrum of the peptide mixture prior to enrichment. In this spectrum
no phosphopeptides were detected which clearly indicates the need for a phosphospecific
enrichment step prior to MS analysis.
Applying the SIMAC approach to the standard peptide mixture resulted in three dif-
ferent peptide fractions. The first fraction was the flow-through from the IMAC material
which was further enriched with TiO2. The second fraction was generated by washing the
IMAC beads with 1% TFA which mainly eluted mono-phosphorylated peptides. This frac-
tion was again further enriched with TiO2. The third fraction was obtained by eluting the
IMAC column with a basic solvent (NH4OH) and this fraction was not enriched with TiO2.
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Figure 3.5: MALDI MS analysis of a peptide mixture containing peptides derived
from 12 standard proteins by trypsin digestion. A MALDI MS spectrum of the
peptides without any prior phosphopeptide enrichment is shown. The proteins included
the phosphoproteins α-casein, β-casein and ovalbumin. No phosphorylated peptide could
be observed in the spectrum.
The MALDI spectra of these fractions are shown in Figure 3.6. For all three fractions, a
clear separation of phosphorylated from non-phosphorylated peptides was obtained. Fur-
thermore, a separation of the mono- from the multi-phosphorylated peptides was achieved.
The first two SIMAC fractions predominately contained peptides carrying one phosphate
group, whereas the basic eluate comprised almost no mono-phosphorylated peptides but
a higher number of multi-phosphorylated peptides. An overview of all phosphorylated
peptides identified after using SIMAC in combination with TiO2 is shown in Table 3.1.
The finding that already in the first fraction a substantial number of mono-
phosphorylated peptides was detected indicates their weak binding to the IMAC resin.
Furthermore, it should be noticed that the first two SIMAC fractions contain the same
phosphorylated peptides. Due to the similarity of the phosphorylated peptides identified
in these two fractions, they were pooled for the following quantitative analysis. This pool-
ing step increases the abundance of the individual phosphorylated peptides in subsequent
LC-MS/MS-based approaches.
In Figure 3.7 the MALDI spectrum for the enrichment of phosphopeptides from the
standard peptide mixture using TiO2 is shown. The spectrum indicates that the enrichment
with TiO2 results in the same mono-phosphorylated peptides as the SIMAC approach,
but only a small fraction of the multi-phosphorylated peptides could be identified using
TiO2 in comparison to SIMAC. This clearly shows the benefit of the SIMAC approach for
phosphopeptide enrichment as compared to the TiO2 approach.
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Figure 3.6: Phosphopeptide enrichment by SIMAC. MALDI MS spectra of 1 pmol of
the tryptic peptides derived from a mixture of 12 standard proteins after phosphopeptide
enrichment using SIMAC and TiO2. MALDI MS spectra from a) the IMAC flow-through
and first wash subsequently enriched by TiO2 b) the acidic (1% TFA) IMAC eluate sub-
sequently enriched by TiO2 c) the basic IMAC eluate. An asterisk indicates the loss of
phosphoric acid and P denotes the number of phosphorylation sites per identified peptide.
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Peptide sequence Protein Mass [Da] MH+ No. of phosphosites
TVDME*STEVFTK α-casein S2 1466.63 1
TVDME*STEVFTKK α-casein S2 1594.71 1
VPQLEIVPN*SAEER α-casein S1 1660.79 1
DIG*SE*STEDQAMEDIK α-casein S1 1927.72 2
YKVPQLEIVPN*SAEER α-casein S1 1952.03 1
FQ*SEEQQQTEDELQDK β-casein 2061.84 1
EVVG*SAEAGVDAASVSEEFR Ovalbumin 2088.93 1
NVPGEIVE*SL*S*S*SEESITR β-casein 2352.73 4
YKVPQLEIVPN*SAEERLHSMK α-casein S1 2548.53 1
NTMEHV*S*S*SEE*SIISQETYK α-casein S2 2618.91 4
VNEL*SKDIG*SE*STEDQAMEDIK α-casein S1 2678.24 3
QMEAE*SI*S*S*SEEIVPN*SVEQK α-casein S1 2703.15 5
QMEAE*SI*S*S*SEEIVPN*SVEQK α-casein S1 2720.98 5
NTMEHV*S*S*SEE*SIISQETYKQ α-casein S2 2748.29 4
EKVNEL*SKDIG*SE*STEDQAMEDIK α-casein S1 2935.30 3
NANEEEYSIG*S*S*SEE*SAEVATEEVK α-casein S2 3008.08 4
RELEELNVPGEIVE*SL*S*S*SEESITR β-casein 3122.01 4
Table 3.1: Phosphorylated peptides in the peptide mixture from the digested
standard proteins identified using SIMAC and TiO2. The phosphorylation sites
are marked with an asterisk. The peptides were analysed by MALDI MS.
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Figure 3.7: Phosphopeptide enrichment by TiO2. MALDI MS spectra of 1 pmol of
the standard peptide mixture after phosphopeptide enrichment by TiO2. The P indicates
the number of phosphorylation sites per identified peptide.
3.2.2 Applying SIMAC to complex samples
Having demonstrated the performance of the SIMAC strategy when applied to a stan-
dard peptide mixture, its suitability for the enrichment of phosphopeptides from a cellular
phosphoproteome was assessed by comparing the enrichment efficiency against the TiO2
approach alone that is commonly used for this purpose. Approximately 200µg of protein
from a 5L cell lysate were used with each strategy and the enriched phosphopeptides were
analysed by LC-MS/MS. A summary of the results obtained is presented in Figure 3.8.
For the SIMAC approach, a total of 863 unique phosphorylated peptides was identified
in the three fractions. These consisted of 469 unique mono-phosphorylated and 394 unique
multi-phosphorylated peptides being observed. Thus, nearly half of all identified peptides
contained two or more phosphosites per peptide. About 84% of these multi-phosphorylated
peptides were identified in the basic fraction. The enrichment efficiency, i.e. the proportion
of phosphorylated peptides among all identified enriched peptides, of the SIMAC approach
was ∼82%. For the TiO2 approach, a total of 345 unique phosphorylated peptides was
identified, the majority (∼85%) being mono-phosphorylated. The enrichment efficiency
was ∼72%. The overlap of the identified phosphorylated peptides between the two methods
amounted to 238 peptides. This low number is probably largely due to the undersampling
of the MS instrument (only the 5 most intense ions are selected for MS/MS per one MS
survey scan).
Collectively, these data show that the SIMAC strategy is in fact suitable for the en-
richment of phosphorylated peptides in highly complex samples. Importantly, the number
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of identified multi-phosphorylated peptides was much higher for the SIMAC method as
compared to the TiO2 method indicating that SIMAC provides a more comprehensive
phosphopeptide pattern than the TiO2 approach alone.
Figure 3.8: Analysis of phosphorylated peptides from 5L cell lysate enriched
by SIMAC or TiO2. The bar chart shows the number of non-, mono- and multi-
phosphorylated peptides identified by the SIMAC approach resulting in three different
fractions and the TiO2 approach with one fraction.
3.3 HILIC as a prefractionation method
The analysis of phosphorylated peptides from a complex sample usually results in the
identification of the phosphopeptides from the most abundant proteins. A prefractionation
prior to LC-MS/MS reduces the sample complexity and improves the identification of
phosphopeptides from low abundant proteins. For a phosphoproteomic approach, several
prefractionation strategies have been described previously including isoelectric focusing
(IEF), strong cation exchange (SCX) or hydrophilic interaction liquid chromatography
(HILIC) [Essader et al., 2005], [Beausoleil et al., 2004], [McNulty and Annan, 2009].
For the present study, HILIC was chosen for prefractionation. For phosphoproteomic
approaches, HILIC is an ideal method as it takes advantage of the hydrophilic character of
the phosphopeptides. HILIC separation was performed after the SIMAC separation and
prior to TiO2 enrichment. Only the combination of flow-through and acidic eluate was
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loaded onto the HILIC column. Previous studies had suggested that HILIC is not suitable
for multi-phosphorylated peptides as they bind to the HILIC material very tightly and
cannot be efficiently eluted using a gradient of organic solvent.
The proteins of a 5L cell lysate were proteolysed with trypsin and the peptides were
subjected to an IMAC phosphopeptide enrichment. The flow-through and acidic eluate
from IMAC were combined and used for HILIC prefractionation. The number and the
size of the collected fractions were optimized in order to achieve a good distribution of
phosphorylated peptides, as well as a manageable number of fractions. The elution profiles
obtained were very similar for all the test samples. A typical example is displayed in Figure
3.9.
Figure 3.9: HILIC elution profile. Elution of tryptic peptides in the flow through and
the acidic eluate from IMAC from the TSKgel Amide 80 column with an increasingly
aqueous solvent. The blue curve displays the UV absorbancy at 214 nm and the pink curve
the gradient of the eluent. Below the x-axis the fraction numbers are displayed.
The resulting fractions were enriched for phosphorylated peptides using the TiO2 ap-
proach and the phosphopeptides were identified and quantified using LC-MS/MS. Figure
3.10 shows an overview of the number of identified phosphorylated peptides and non-
phosphorylated peptides in the different HILIC fractions. The largest fraction, which com-
prised the flow-through from the HILIC column loading, contained only few phosphorylated
peptides. This was probably due to the elution of mainly hydrophobic peptides which do
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not bind to the column in 80% ACN. The majority of the phosphopeptides eluted after
a lag period of ∼14 min corresponding to an ACN concentration of 65%. HILIC prefrac-
tionation in combination with the TiO2 approach for phosphopeptide enrichment resulted
in a good enrichment efficiency. Overall, 70% of the subsequently identified peptides were
found to be phosphorylated. Interestingly, in the fractions 8 to 16, an efficiency of around
95% was obtained. More than 85% of the overall identified phosphorylated peptides were
contained in these fractions.
Figure 3.10: Distribution of phosphorylated and non-phosphorylated peptides
in the HILIC fractions. Elution of tryptic peptides in the flow through and the acidic
eluate from IMAC from the TSKgel Amide 80 column with an increasingly aqueous solvent.
The black bars display the number of identified phosphorylated peptides per fraction. The
red bars display the number of identified non-phosphorylated peptides per fraction.
The overall redundancy of the identified phosphorylated peptides was ∼20%, meaning
∼80% of the individual peptides were found in only one fraction.
Taken together, HILIC prefractionation prior to TiO2 enrichment is a very efficient
method to reduce sample complexity and improve the overall identification of phosphopep-
tides. Sample prefractionation resulted in a higher number of identified phosphorylated
peptides than using SIMAC and TiO2 alone. Without prefractionation, ∼900 unique phos-
phorylated peptides were identified, whereas using HILIC the number of identified phos-
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phorylated peptides increased to ∼3000. Furthermore, HILIC by itself already enriches
phosphopeptides as indicated by the increase in the numbers of phosphorylated peptides
per fraction during the course of the elution shown in Figure 3.10.
3.4 The phosphoproteome of 5L cells
3.4.1 Identified phosphorylation sites
Eight individual experiments involving SILAC labelling and exposure of the cells to
DMSO/TCDD (1 nM) for 0.5 - 2 hours, proteolysis, HILIC prefractionation and phos-
phopeptide enrichment with subsequent analysis using LC-MS/MS were performed. In
these experiments, 800µg of protein were used as starting material for each analysis. In
total, 5648 different phosphorylated peptides comprising distinct 6573 phosphosites were
identified. For these peptides, 2156 corresponding phosphoproteins were identified. The
major part, ∼84% of the identified peptides, was phosphorylated at serine residues, while
∼14% were phosphorylated at threonines and only ∼2% were phosphorylated at tyrosines
(Figure 3.11(a)). This distribution is consistent with the frequencies observed in other
large-scale studies [Olsen et al., 2006] [Van Hoof et al., 2009]. The majority of the pep-
tides was mono-phosphorylated (∼86%), but a substantial number of peptides (∼12%)
was doubly phosphorylated. Only ∼2% of all identified peptides contained three or more
phosphorylation sites (Figure 3.11(b)). The number of multi-phosphorylated peptides was
only slightly higher than that reported in other publications ([Hou et al., 2010]).
All MS files of the phosphopeptides were searched against the rat sequence library in
the International Protein Index (IPI) protein sequence database using an inhouse Mascot
server. The acquired IPI accession numbers of the identified phosphorylated proteins were
mapped against the Uniprot database to achieve more detailed information on the pro-
teins. The Uniprot database consists of two different subdatabases, the Swiss-Prot and
the TrEMBL database. Of the 2156 phosphoproteins identified with IPI, only 688 could
be mapped to a Swiss-Prot accession number and 452 phosphoproteins could be mapped
to a TrEMBL accession number. In the Swiss-Prot database, all proteins are manually
annotated and reviewed and multifaceted information like known phosphosites and protein
functions is available. In contrast, in the TrEMBL database, the proteins are automat-
ically annotated and not reviewed. Like IPI, TrEMBL does not supply information on
known protein modifications, for example phosphorylation. For this reason, only the 688
phosphoproteins mapped to Swiss-Prot were selected for the analysis of whether their phos-
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(a) Overview of the distribution of pSer, pThr and pTyr.
(b) Overview of mono- and multi-phosphorylated peptides
Figure 3.11: Analysing the phosphoproteome of 5L cells.
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(a) Phosphoproteins (b) Phosphopeptides
Figure 3.12: Overview of known, ”known by similarity” or novel phosphoproteins
and -peptides identified in the present study. Only 688 phosphoproteins (with 1948
phosphorylated peptides) identified with IPI could be mapped to a Swiss-Prot accession
number.
phorylation sites had been identified before. Among these 688 rat phosphoproteins, only 73
proteins were previously known to be phosphorylated and 367 proteins were known to be
phosphorylated ”by similarity”, which means that they were known to be phosphorylated
in other species such as mouse or human, but not in rat. A large portion of the 248 pro-
teins had not been known to be phosphorylated until now. With respect to the identified
phosphopeptides, the actual phosphosite had already been described for 197 of them. The
main part of the phosphosites (1207) had been known ”by similarity” and 544 phosphosites
were novel. These results clearly show that the present study provides substantial new in-
formation on the rat phosphoproteome. The ”known”, ”known by similarity” and ”novel”
phosphoproteins and phosphorylation sites are listed in the Table 9 in the Appendix.
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3.5 Multiple testing for finding statistically signifi-
cantly ”regulated” phosphopeptides
3.5.1 Normalisation
Before the p-values for the individual ratios of the phosphopeptides from DMSO- and
TCDD-treated cells were calculated, a normalisation of the ratios was performed in order
to remove biases introduced by sample preparation, i.e. differences in the amount of
protein from the ”light” and the ”heavy” state in the sample. The ratios were calculated
by MSQuant based on the intensity of the first isotopic peak of the particular SILAC pairs
in the MS spectra. The intensity value of the ”heavy” state (TCDD-treated) is divided
by the intensity value of the ”light” state (DMSO-treated) (Regulation factor H/L). In
order to find the right normalisation method for the data sets, ratios-vs-average MA plots
were drawn for all biological replicates of the individual time points. For MA plots, the
peptide ratios were plotted against the average of the peptide intensities. MA plots are very
common visualization tools originally developed for the micro-array area and give a quick
overview of the data. Figure 3.13 shows the MA plots for the biological replicates of the 30-
min exposure period before normalisation. The plots showed no definite trend with respect
to intensity and ratio indicating that peptides with low intensity had ratios similar to those
of peptides with high intensity. Nearly all peptides of the three plots were distributed
around one value showing that a global normalisation method was appropriate. Therefore,
the ”median normalisation” at the peptide level was applied. The ratios calculated by the
MSQuant program were normalised by subtracting the ratios with a fixed value selected
such that the median of the logarithmized ratios became zero [Do and Choi, 2006].
In Figure 3.13, a lowess trend line (blue) is shown for the unnormalised plots which is
fitted through the data points. Lowess is a local regression using a sliding window across a
range of intensity levels and reflects the trend of the data points [Smyth and Speed, 2003].
A second, horizontal line (red) is displayed in the unnormalised plots. This line intersects
the y axis at y=0 and displays the median of 0. In all three unnormalised plots both lines
were very similar, indicating that the correction factors for the normalisation of the data
were very small and that the biases introduced by the sample preparation were minimal.
In Figure 3.14, the MA plots for the replicates for 30 min after normalisation are shown.
For the 1 hour and 2 hours data, the MA plots looked very similar and are shown in the
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(a) 30 min DMSO/TCDD; Biological Replicate 1 (b) 30 min DMSO/TCDD; Biological Replicate 2
(c) 30 min DMSO/TCDD; Biological Replicate 3
Figure 3.13: MA plots of peptides before normalisation. Unnormalised peptide
ratios were plotted as ratios-vs-average (MA) plots. The log2 ratios H/L (y-axis) are
plotted against the log2 average of the peptide intensities H (heavy = TCDD treated) and
L (light = control). The blue line is a lowess line, the red line indicates y = 0. a), b) and
c) show the data from the three different biological replicates obtained after treatment of
the cells with DMSO/TCDD for 30 min.
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Exposure Period
Pearson correlation coefficient
Biological Replicate 1 Biological Replicate 2 Biological Replicate 3
30 min 0.79 0.80 0.63
1 h 0.75 0.68 0.73
2 h 0.84 0.74 -
Table 3.2: Calculated Pearson correlation factors for the biological replicates of
the different time points. The correlation coefficients were calculated for the peptide
ratios of the biological replicate in question against the mean of the ratios of the biological
replicates of the time point.
Appendix (see Figures 1, 2, 3, 4). These data sets were also normalised using the ”median
normalisation” approach.
3.5.2 Correlation
To assess the conformity of the biological replicates of the individual exposure periods, the
Pearson correlation coefficients were calculated. The coefficients of the correlation between
the different biological replicates are shown in Table 3.2.
Pearson correlation coefficients can vary between -1 and 1, where 1 indicates a perfect
correlation between the biological replicates. From all replicates of all time points positive
correlation coefficients were obtained. In two cases the coefficient was below 0.7 (0.68 and
0.63). For these two data sets, the correlation with the other replicates of the same time
point was ”weakly positive” (range of +0.3 to +0.7), but close to a ”strongly positive”
correlation (+0.7 to +1.0) [Sachs and Hedderich, 2009]. These data sets were therefore
included in the statistical tests.
3.5.3 Statistical analysis
To identify the statistically significantly regulated phosphopeptides for the particular
time points, an empirical Bayes moderated t-test was applied to the data sets using the
R/Bioconductor package limma. For the statistical tests, the biological replicates of each
time point were merged together and peptides found in only one replicate were removed.
Thus, the tests were only performed on peptides found at least twice. A well established
significance threshold for accepting peptides as regulated is p ≤ 0.05. All peptides with
a calculated p-value below this threshold were considered as differentially regulated. A
45
CHAPTER 3. RESULTS
(a) 30 min DMSO/TCDD; Biological Replicate 1 (b) 30 min DMSO/TCDD; Biological Replicate 2
(c) 30 min DMSO/TCDD; Biological Replicate 3
Figure 3.14: MA plots of peptides after normalisation. Normalised peptide ratios
were plotted as ratios-vs-average (MA) plots. The log2 ratios H/L (y-axis) are plotted
against the log2 average of the peptide intensities H (heavy = TCDD treated) and L (light
= control). The red line indicates y = 0. a), b) and c) show the data from the three
different biological replicates obtained after treatment of the cells with DMSO/TCDD for
30 min.
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total of 126, 140 and 84 peptides with p ≤ 0.05 were identified for the exposure periods
30 min, 1 hour and 2 hours, respectively. It appeared possible, however, that the mod-
erated t-tests had resulted in many false positives, i.e. peptides erroneously accepted as
regulated (type 1 error). To control for the number of false positives, the false discovery
rate (FDR) based on the p-value was estimated. Various methods for controlling FDR are
available, and for the present study the q-value method [Storey and Tibshirani, 2003] was
chosen as it had been shown [Qian and Huang, 2005] to give the highest apparent power in
comparison to various other FDR controlling methods, such as the approach of Benjamini
and Hochberg [Benjamini and Hochberg, 1995]. Peptides with a q-value equal or below
0.05 were accepted as statistically significantly regulated, i.e. with a value of p ≤ 0.05 an
error rate of 5% was accepted. For the 30 min data sets, no peptides were identified with a
q-value equal or below 0.05. For the 1 hour data sets, 4 peptides had a q-value below this
threshold and for the 2 hours datasets, 6 peptides had a q-value below 0.05 (see below).
Figure 3.15 shows two different volcano plots for each time point. The volcano plot
is a scatter plot which displays the fold-changes (FC) versus a measure of the statistical
significance of the change [Cui and Churchill, 2003]. For the left-sided panel for each time
point, the log FC values of the normalised peptide ratios were plotted against the log p-
values, i.e. against the measure of statistical significance. For the panel on the right side
for each time point, the log FC values were plotted against the log q-values, i.e. against
the measure of statistical significance after correction for false positives. The horizontal
dashed line in all plots displays the significance threshold of 0.05 for the p- and the q-
values. The two vertical dashed lines in all plots are set at an FC value of 1.5 for up- and
down-regulation.
The volcano plots where the log FC values were plotted versus the log p-values (left
panels) exhibit many peptides with a p-value p ≤ 0.05 (above the horizontal dashed line).
However, no peptides for the 30 min plot and only few for the 1 hour and 2 hours plots
occur outside the region edged by the two vertical lines indicating an FC >1.5. This
observation indicated a marked discrepancy between the FC method and the statistical
test. In contrast, the volcano plots where the log FC was plotted versus the log q-values
(right panels) exhibit a very homogeneous picture, as nearly all peptides with an FC of >1.5
are also identified as significantly regulated (p ≤ 0.05) after correction for false positives.
An exception was one peptide from the 1 hour dataset which exhibited a q-value below
the threshold of 0.05 whereas the FC was inside the 1.5 FC range. The variance of this
data set was very low, which was taken into account by the statistical test but not by the
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(a) 30 min DMSO/TCDD exposure
(b) 1h DMSO/TCDD exposure (c) 2h DMSO/TCDD exposure
Figure 3.15: Volcano plots for each time point.The plots display the relationship
between statistical significance and FC for all peptides subjected to the statistical tests.
The log2 FC (x-axis) was plotted against the -log10 p-value (y-axis) (left) and against the
-log10 q-value (y-axis) (right). The horizontal dashed line indicates the p- and q-value
threshold of 0.05. The two vertical dashed lines indicate the 1.5 FC threshold.
48
3.6. PEPTIDES WITH ALTERED PHOSPHORYLATION AFTER TREATMENT OF
THE 5L CELLS WITH TCDD
FC threshold. Thus, the present study essentially yielded the same results with respect
to the identification of regulated peptides when the classification relied on a statistical
test in combination with the calculation of the q-value and when the classification was
based on the FC of 1.5. In contrast, the Bayes moderated t-test alone yielded many false
positive results. These observations showed that both a biological threshold of 1.5 FC and
a statistical threshold of q ≤ 0.05 are appropriate for this data set. Peptides which were
found in only one of the biological replicates were removed before applying the moderated
t-test to the datasets. These peptides were analysed separately to identify regulated ones.
A cut off value of 1.5 FC was used based on the results of the volcano plots. The results
will be discussed separately from the results of the statistical tests in the next chapter.
3.6 Peptides with altered phosphorylation after treat-
ment of the 5L cells with TCDD
3.6.1 Time course of the induction of CYP1A1
In the present study, the 5L cells were treated with 1 nM TCDD for 0.5, 1 and 2 hour(s).
These relatively short exposures were not expected to result in significant alterations in
protein levels as a consequence of TCDD-altered gene expression which would complicate
the comparison of phosphopeptide abundances in control cells and TCDD-treated cells. To
obtain information on the time course of the stimulation of gene expression by TCDD in 5L
cells at the protein level, the induction of cytochrome P4501A1 (CYP1A1) was analyzed
with respect to the protein level and the enzymatic activity in the cells.
Figure 3.16 shows the results obtained from Western Blotting experiments. They indi-
cate that no alteration in protein abundance could be detected after TCDD exposures of
1 hour. A significant up-regulation was observed after 1.5 hours and longer exposure peri-
ods. The measurement of the 7-ethoxyreorufin deethylase (EROD) activity, an enzymatic
activity associated with CYP1A1, did not show any detectable alteration at 0.5 to 2 hours
and was thus a less sensitive approach for the detection of alterations in CYP1A1 protein
level (Figure 3.17).
Thus, since CYP1A1 is the most rapidly and most potently induced target gene of
TCDD in essentially every cell type, it appeared highly unlikely that the exposure of the
cells to TCDD for 0.5 and 1 h would result in changes in the abundance of proteins even if
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Figure 3.16: Time course of the induction of CYP1A1 protein by TCDD in 5L
cells. Cells were exposed to 1 nM TCDD for the times indicated. Total cell lysates were
prepared and analysed on 12% PAGE gels. Proteins were electroblotted, and CYP1A1
and actin (loading control) were visualised using specific antibodies and ECL detection.
Bands were quantitated by densitometry. A), Sections of the respective blots from one
experiment out of three which yielded very similar results. B), Means ±SD from three
independent experiments. * p < 0.01, ** p < 0.001
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Figure 3.17: Time course of the induction of EROD activity by TCDD in 5L
cells. Cells were exposed to 1 nM TCDD for the times indicated, and EROD activity
was determined in whole cell lysates. Results are the means ±SD from three independent
experiments. *, p < 0.05; **, p < 0.00001.
they were transcriptionally induced by the dioxin. For the 2 h exposure period, however,
alterations of the cellular levels of such proteins would appear possible.
3.6.2 Peptides with altered phosphorylation after 30 min TCDD
treatment
For the protein samples from 5L cells treated with TCDD for 30 min, 1368 phosphorylated
peptides were found in at least two of the biological replicates and used for the statistical
test to calculate the p-value and q-value of the individual peptides. With the set significance
threshold of q = 0.05, no significantly regulated phosphorylated peptides were found.
3942 peptides were found in only one of the three biological replicates. This number is
surprisingly high and indicates a low overlap between the biological replicates. The anal-
ysis of these peptides applying an FC threshold of 1.5 identified 4 peptides as regulated
(Table 3.3). For two of the four proteins from which the regulated peptides were derived
(Transcription intermediary factor 1-beta and RCG52671, isoform CRA a), other phospho-
rylated peptides were identified. These, however, showed regulation factors close to 1 (see
Table 8 in the Appendix). This suggests that for these two proteins the phosphorylation
of the specific phosphosite was affected by TCDD but not their overall protein level.
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For the Isoform 1 of Aryl hydrocarbon receptor, one phosphorylated peptide was ob-
served. It exhibited a regulation factor of 0.68 just below the threshold of 1.5 used as a
cut-off value for the classification of a peptide as ”regulated”.
3.6.3 Peptides with altered phosphorylation after 1 hour TCDD
treatment
For the protein samples from cells treated with TCDD for 1 hour, 1075 phosphorylated
peptides occurred in at least two of the three replicates. Four peptides with a q-value
<0.05 were found (Table 3.4). Three of these peptides were up-regulated and one was
down-regulated.
For the protein ”similar to AHNAK”, 26 different phosphorylated peptides were iden-
tified, but only one of them was significantly regulated (shown in Table 8, Appendix).
The others exhibited regulation factors between 0.9 and 1.2. Interestingly, for the regu-
lated phosphorylated peptide LPSGpSGAASPTTGSAVDIR another phosphosite (LPSGS-
GAApSPTTGSAVDIR) was identified which was not regulated. The regulated phospho-
rylation occurred on y15/b5 and the non-regulated on y11/b9. Inspection of the MS/MS
spectra of both forms of the peptide verified the results obtained from MSQuant indicating
that the peptide was phosphorylated at different sites. The extracted ion chromatograms
(XIC)1 as well as the MS- and the MS/MS spectra of both forms of the peptide are shown
in Figures 3.18, 3.19, 3.20. Whereas for both peptides the y10 fragment ion had the same
mass, the y11 fragment showed a loss of a phosphate group for the peptide LPSGSGAAp-
SPTTGSAVDIR but not for the peptide LPSGpSGAASPTTGSAVDIR. Both forms of the
peptide were identified side-by-side due to their different retention times on the C18 col-
umn. Phosphate groups close to the N-terminus of the peptide can form a salt bridge with
the free amide group. This reaction results in an increased hydrophobicity of the peptide
and, therefore, a different retention behaviour on the RP-column. This could explain the
different retention times of the two phospho-species.
For the Rdbp protein two different phosphorylated peptides were identified. Both
exhibited similar regulation factors of 1.64 and 1.79 (Table 3.4 and 3.5). Whereas the
peptide SMpSADEDLQEPSR was identifed in more than one biological replicate (Table
3.4), the peptide SLpSEQPVVDTATATEQA was found in only one sample (Table 3.5).
1The extracted ion chromatogram (XIC) is the chromatographic profile of an ion with a partic-
ular m/z. An XIC provides information about the elution time and length of the particular ion
[Lottspeich and Engels, 2006].
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(a) Extracted Ion Chromatogram; y15/b5
(b) Extracted Ion Chromatogram; y11/b9
Figure 3.18: Phosphosite-specific quantitation of an AHNAK peptide carry-
ing different phosphorylations - Extracted ion chromatograms. The extracted
ion chromatograms for the peptides LPSGpSGAASPTTGSAVDIR (a) and LPSGSGAAp-
SPTTGSAVDIR (b) are shown. The blue peak indicated the XIC derived from the ”light”
peptide from the DMSO-treated cells, the green peak the XIC derived from the ”heavy”
peptide from the TCDD-treated cells.
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(a) MS spectrum; y15/b5
(b) MS spectrum; y11/b9
Figure 3.19: Phosphosite-specific quantitation of an AHNAK peptide carrying
different phosphorylations - MS spectra. The MS-spectra for the peptides LPSGpS-
GAASPTTGSAVDIR (a) and LPSGSGAApSPTTGSAVDIR (b) are shown. The monoiso-
topic mass at m/z 914.43 (z +2) was derived from the ”light” peptide (DMSO-treated cells)
and that at m/z 917.44 (z +2) from the ”heavy” peptide (TCDD-treated cells). The un-
normalised ratios between the monoisotopic peak intensities of the ”heavy” and the ”light”
labelled forms were 2.008 (a) and 1.176 (b), respectively.
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(a) MS/MS spectrum; y15/b5
(b) MS/MS spectrum; y11/b9
Figure 3.20: Phosphosite-specific quantitation of an AHNAK peptide carrying
different phosphorylations - MS/MS spectra. The MS/MS spectra annotations for
the two different phosphopeptides (LPSGpSGAASPTTGSAVDIR (a) and LPSGSGAAp-
SPTTGSAVDIR (b)) are shown. A comparison of both fragmention spectra indicates
two different phosphorylation sites for the same peptide, on serine y15 and serine y11,
respectively. 57
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As a consequence of the similar regulation factors it was not possible to decide whether
their upregulation reflected a higher phosphorylation level of these peptides or a higher
expression level of the Rdbp protein. This question has been addressed in the following
chapter 3.6.4.
For the protein Pragmin two other phosphorylated peptides were found in addition to
the regulated one shown in Table 3.4. These peptides were not regulated suggesting that the
upregulation of the peptide EAVQPEPIpYAESAK reflected an elevated phosphorylation
(Table 8).
For the protein Interferon-inducible double stranded RNA-dependent protein kinase
activator A no other peptides were found.
2774 phosphorylated peptides where observed in only one of the biological replicates.
Seven of them were up-regulated and one was down-regulated (Table 3.5). For 5 of the
corresponding proteins, namely zinc and double PHD fingers family 2, UBX domain-
containing protein 4, DENN/MADD domain containing 5A, similar to Chromosome-
associated kinesin KIF4A and Isoform 1 of Protein LYRIC, other phosphorylated peptides
were found which were all not regulated (Table 8) suggesting that the upregulation of their
phosphopeptides shown in Table 3.5 reflected specifically increased phosphorylation events.
In addition, for UBX domain-containing protein 4 the regulated phosphorylated peptide
was also present in its unphosphorylated state, and this peptide was neither regulated
(Table 8). The spectra of both forms of this peptide are shown in the Appendix (14, 15).
3.6.4 Peptides with altered phosphorylation after 2 hours TCDD
treatment
For this treatment period, two biological replicates were analysed. As a consequence of the
lower number of samples, a lower number of phosphorylated peptides was observed. 883
peptides occurred in both replicates and were taken to calculate the p- and q-values. 83
peptides with a p-value <0.05 were identified. After FDR correction, 6 peptides remained
significantly regulated (q-value <0.05) of which 5 were up-regulated and 1 was down-
regulated (Table 3.6).
For (TIF1β), Isoform 1 of Protein LYRIC and ”similar to AHNAK”, further phospho-
peptides were identified which were not regulated (Table 8). For the Rdbp protein two
peptides were found and, as had been observed for the 1 hour data set, both peptides
were up-regulated. Again, the peptide SMpSADEDLQEPSR was found in two biological
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replicates and the peptide SLpSEQPVVDTATATEQAK in only one replicate. Thus, the
regulated phosphosites were the same for the two time points.
1997 phosphorylated peptides were observed in only one of the two biological replicates.
10 of them were up-regulated and 6 were down-regulated (Tables 3.7 and 3.7). For the
following proteins more phosphopeptides than just the regulated one were identified, but
none of these was regulated suggesting that the level of these proteins in the cells was not
affected by TCDD: Cdc42 effector protein 1, RNA binding motif, single stranded interacting
protein 2, ataxin 2, PTPRF interacting protein, binding protein 1, p38alpha, similar to zinc
finger, ZZ type with EF hand domain 1, 106 kDa protein and MARCKS-related protein
(Table 8; Appendix).
Since for the Rdbp protein two upregulated phosphorylated peptides, but no others,
were observed both for the 1 hour and the 2 hours exposure period, the possibility remained
the up-regulation reflected an increase in the level of Rdbp protein by TCDD rather than
increased phosphorylations. To address this problem, the level of the Rdbp protein at the
different time points was examined by Western blotting. Figure 3.21 shows that treatment
of the 5L cells with TCDD for 0.5 – 4 hours did not cause any detectable alteration in
the amount of Rdbp protein, supporting the conjecture that the observed up-regulation
actually reflected specifically increased phosphorylations of Rdbp.
3.6.5 Summary of the identified peptides with altered phospho-
rylation after TCDD treatment
For the three periods of TCDD exposure, 7 proteins carrying specific phosphorylation sites
significantly regulated by TCDD as analysed by the moderated t-test and the q-value
calculation were found. In addition, 23 proteins with TCDD-regulated phosphorylation
sites were observed in only one biological replicate but with an FC of ≥ 1.5. For all
regulated phosphorylated peptides the MS/MS spectra where manually validated and are
shown in the Appendix. For the majority of the proteins with altered phosphorylation
at specific sites further phosphopeptides were observed that were not regulated indicating
that specific phosphorylations, but not the level of the protein, were affected by TCDD.
A short overview of all proteins with TCDD-regulated phosphorylation and the affected
phosphorylation sites for all exposure periods is shown in Tables 3.8 and 3.8. An extended
version of this table, providing more detailed information, can be found in the Appendix
(Table 7).
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(a)
(b)
Figure 3.21: Western blot analysis of the effects of TCDD on Rdbp protein
abundance in 5L cells. Cells were exposed to DMSO or 1 nM TCDD for the times
indicated. Total cell lysates were prepared and analysed on 12% PAGE gels. Proteins
were electroblotted, and Rdbp and actin (loading control) were visualized using specific
antibodies and ECL detection. Bands were quantitated by densitometry. (a), Sections of
the respective blots from one experiment out of three which yielded very similar results.
(b), Means ±SD from three independent experiments.
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3.7 Mechanism of the calcium dependence of TCDD-
induced gene activation in 5L cells
For the protein AHNAK, highly significant increases in the phosphorylation of a spe-
cific residue, Ser212, were observed in four of the experiments with 1 hour and 2 hours
exposures to TCDD. Since one of the known functions of AHNAK is the regulation
of L-type voltage-gated Ca2+ channels in the plasma membrane [Haase et al., 1999],
[Hohaus et al., 2002], [Alvarez et al., 2004] and since an increased Ca2+ influx is required
for the AhR/ARNT-dependent transcriptional activation of target genes of TCDD like
CYP1A1 [Monteiro et al., 2008], the potential role of L-type voltage-gated Ca2+ channels
in the regulation of CYP1A1 expression was assessed by determining the effect of inhibitors
of these channels on the inducibility of CYP1A1 protein in 5L cells by TCDD using West-
ern blotting. In addition, the effects of certain experimental conditions and other inhibitors
and agents interfering with different aspects of Ca2+ homeostasis were investigated. The
results of these experiments are shown in Figure 3.22. The incubation of the cells with
TCDD for 4 h or 8 h strongly increased CYP1A1 protein level. The concurrent presence
of the L-type voltage-gated Ca2+ channel inhibitors amlodipine, diltiazem or nifedipine
had no significant effect on CYP1A1 induction indicating that these Ca2+ channels are
unlikely to be involved in the regulation of TCDD-induced gene activation. By contrast,
induction of CYP1A1 was completely abrogated in the absence of Ca2+ from the culture
medium or in the presence of the cell-permeable Ca2+ chelator BAPTA-AM indicating a
requirement for extra- and intracellular Ca2+ ions in this process. The presence of 2-APB,
an inhibitor of store-operated Ca2+ entry and, inconsistently, inositol 1,4,5-trisphosphate
receptor-mediated Ca2+ release from the endoplasmic reticulum [Bootman et al., 2002],
also blocked the action of TCDD completely. Supplementation of the medium with the
specific Ca2+/calmodulin kinase I (CAMKI) inhibitor KN-93 also fully prevented CYP1A1
induction by TCDD. In contrast, the KN-93 analogue KN-92, which does not inhibit
CAMKI, was without any effect at 4 h and only slightly reduced CYP1A1 protein level
after 8 h. The calmodulin antagonist W-7, which binds to the calmodulin binding site of
the enzyme, slightly inhibited CYP1A1 induction after 4 h but completely abolished the
strong induction by TCDD observed after 8 h. The latter observations are fully consistent
with those reported by Monteiro et al. [Monteiro et al., 2008] for human mammary MCF-7
cells and primary macrophages.
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Figure 3.22: Western blot analysis of the effects of inhibitors and agents inter-
fering with Ca2+ homeostasis on the inducibility of CYP1A1 protein by TCDD
in 5L cells. Following pre-incubation of the cells with amlodipine (”Amlo”, 10µM), dil-
tiazem (”Dil”, 50µM), nifedipine (”Nife”, 50µM), BAPTA-AM (”BAPTA”, 50µM), W-7
(50µM), KN-93 (50µM), KN-92 (50µM) or Ca2+-free medium for 15 min, DMSO or TCDD
(1 nM) was added and the incubation continued for 4 and 8 h. Total cell lysates were pre-
pared and analysed on 12% PAGE gels. Proteins were electroblotted, and CYP1A1 and
actin (loading control) were visualized using specific antibodies and ECL detection. Sec-
tions of the respective blots from one experiment out of three which yielded very similar
results are shown.
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Thus, the present data support the notion that AhR/ARNT-dependent induction of
CYP1A1, and probably other AhR/ARNT target genes, in 5L cells is dependent on the
availability of extra- and intracellular Ca2+, that store-operated Ca2+ channels, but not
L-type voltage-gated Ca2+ channels, mediate Ca2+ entry into the cells and that active
CAMKI is required. With respect to AHNAK, the data indicate that the observed up-
regulation of Ser212 phosphorylation of AHNAK by TCDD is unlikely to be functionally
important for the regulation of Ca2+ entry into cells by TCDD.
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Chapter 4
Discussion
The present phosphoproteomic study was performed with the aim to identify hitherto
unknown changes in protein phosphorylation caused by TCDD in 5L cells independent
of TCDD-induced gene expression. In order to detect these alterations, a quantitative
”global” comparison of the relative abundances of phosphorylated peptides using a shot-
gun phosphoproteomics approach was taken. Cells were differentially SILAC-labelled with
amino acids containing stable heavy isotopes to enable the discrimination of peptides in
control cells and TCDD-treated cells and then treated for short periods (0.5, 1 and 2 hours)
with DMSO or TCDD. Following combination of control cells and treated cells in a single
sample, proteins were proteolysed and phosphopeptides were enriched using the SIMAC
approach, fractionated by HILIC and analyzed by LC-MS/MS. This strategy yielded in-
formation on the relative amounts of the phosphopeptides in control and TCDD-treated
cells and identified both the phosphorylation sites and the corresponding phosphoproteins.
4.1 Methodological aspects
In the following, several methodological aspects of the present quantitative phosphopro-
teomics study will be discussed briefly.
4.1.1 SILAC labelling
In order to detect and quantitate the changes of protein phosphorylation between control
cells and TCDD-treated cells, the SILAC approach was taken. SILAC is a very precise
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method for the relative quantitation of peptides and proteins and allows the detection of
relatively small differences between different cell states [Park et al., 2006].
The pooling of control and TCDD-exposed cells directly after cell lysis was expected
to allow a very accurate quantitation of the phosphorylated peptides. This expectation
was fulfilled as the MA plots for the data sets before normalisation shown in Section 3.5.1,
clearly indicated that the error introduced by sample handling was minimal.
In addition to the advantage that every tryptic peptide except for the C-terminal one
becomes isotopically labelled when heavy arginine and lysine are used for SILAC labelling,
the use of these amino acids in their 15N- and 13C-labelled form provides the benefit that
the heavy isotopes do not affect the chemical behaviour of the peptides. This is in con-
trast to the use of deuterated amino acids which result in an altered LC retention of the
peptides [Zhang et al., 2001]. Deuterated peptides elute from the reversed phase material
earlier than peptides containing the light hydrogen due to a different transient dipole of
the 2H-C bond [Ong et al., 2003a] which complicates the following quantitation by MS.
A potential problem associated with the use of isotopically labelled arginine for SILAC
labelling is the fact that fast growing cells can metabolically convert an excess of arginine
into proline [Ong et al., 2003b]. This results in the formation of isotopically labelled proline
from labelled arginine and, thus, the appearance of multiple peaks for proline-containing
peptides which will complicate their quantitation. The 5L cells exhibit this interconversion
(not shown), and therefore a solution to this problem was employed that had recently been
described by van Hoof et al. [Van Hoof et al., 2007]. It involves the use of 15N4-arginine as
”light” arginine label for the control cells and 13C6
15N4-arginine as ”heavy” arginine label
for the TCDD-treated cells. The method is based on the assumption that for both forms
of heavy arginine, the arginine-to-proline conversion is quantitatively equal. In the MS
spectra, light and heavy arginine-containing peptides can then be quantitated accurately
when the analysis is based on the first monoisotopic peak of the two types of peptides. This
strategy is very easy to adapt to the cells and allows a precise relative peptide quantitation
in any proliferating cell. However, this choice of isotopes complicated the data analysis
in the present study as both open-source software packages available for the analysis of
SILAC quantitation data, MSQuant and MaxQuant, cannot handle this labelling type.
Only after changes in the source code of MSQuant this program was able to quantify this
type of labelling. An unavoidable drawback of the SILAC method as well as any other
isotopic labelling strategy is the increased sample complexity as every single peptide results
in two different peaks in the MS spectrum [Ytterberg and Jensen, 2010]. For both mass
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peaks a MS/MS spectrum will be acquired which will not deliver additional information
but reduce the number of peptide identifications.
4.1.2 A comprehensive phosphoproteomic analysis?
In the course of establishing the experimental protocols for this project, it was seeked to
keep the amount of starting material low in order to be able to use the same phosphopep-
tide enrichment set-up for future experiments on tissue samples which may provide only
limited amounts of protein. In the present study, 5648 unique phosphorylated peptides
were identified from a relatively low amount of protein, 800µg, which compares favourably
with results from other large-scale phosphoproteomics studies which identified roughly
similar numbers of phosphorylated peptides but started with a higher amount of protein.
Thus, Rinschen et al. identified 3869 unique phosphopeptides from an initial 4 mg of pro-
tein [Rinschen et al., 2010] and Hou et al. identified 2230 unique phosphopeptides starting
with 4.5 mg [Hou et al., 2010].
Only few of the identified phosphopeptides were found to be differentially ”regulated”
following treatment of the cells with TCDD in the present study. There are two possible ex-
planations for this outcome. First, it appears likely that the action of TCDD mainly takes
place on the genomic level by altering gene expression and only few signalling pathways
are directly affected by TCDD at early time points. A second reason for the low number
could be the enrichment and identification of phosphorylated peptides mainly from highly
abundant proteins which are unaffected by TCDD. The latter problem could be attenu-
ated by a further reduction of sample complexity. As a result, a higher number of peptide
identifications and a higher number of differentially regulated phosphopeptides detected
would be expected. In this study, the implementation of HILIC as a method for phos-
phopeptide prefractionation in the experimental protocol already increased the number of
identified peptides by more than three times as shown in Chapter 3.3. However, several
other strategies for sample preparation or changes of the MS set-up may improve the num-
ber of identifications, particularly for less abundant phosphoproteins. In the following, a
few options will be shortly discussed.
Cell fractionation before or after cell lysis will result in reduced sample complexity on
the protein level. Moreover, it would be expected to provide a detailed overview of the
alterations of the phosphoproteome in the different cell compartments. Another possibility
to increase the number of identifications would be the implementation of a gas-phase frac-
tionation (GPF) at the MS level [Spahr et al., 2001]. Instead of acquiring a sample over
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one wide mass-to-charge range, the MS spectrum is split into several smaller mass ranges to
select ions for fragmentation. GPF has been demonstrated to result in higher proteome cov-
erage than the LC-MS/MS approach without fractionation [Kennedy and Yi, 2008]. In the
present study, the five most intense peptide ions from the survey scan (MS) were selected
for fragmentation to reveal the peptide sequence. The fragmentation method employed
was CID, where the peptides collide with an inert gas resulting in backbone fragmentation
of the peptides. This type of fragmentation is currently the most commonly used method
in mass spectrometry-based proteomics. Recently, a new fragmentation technique, elec-
tron transfer dissociation (ETD), was introduced [Syka et al., 2004]. ETD has been shown
to be highly suitable for the identification of labile post-translational modifications which
remain intact on the peptide during fragmentation. The fragmentation of phosphorylated
peptides using ETD results in a higher number of identified peptides [Swaney et al., 2009].
The overlap between the phosphopeptides identified with ETD or CID is fairly low which
demonstrates the complementary character of the two methods. CID fragmentation is
more efficient for peptides with a charge state of 2 or 3 and a mass range of 400 - 600
m/z. ETD, on the other hand, results in better fragmentation spectra for peptides with
a higher charge state and higher m/z range. The group of Coon used these observations
to develop a special algorithm, the so-called “decision tree” (DT) [Swaney et al., 2008],
where the fragmentation method is chosen automatically based on the mass and charge
state of the peptide in question. Using the DT approach, the number of identified peptides,
particularly that of phosphorylated ones, could be increased considerably. Thus, there are
various options to increase the number of peptide identifications and, therefore, to analyse
proteins of low abundance. However, all of these methods require a certain amount of
starting material and a lot of measurement time on the mass spec instruments. For this
study, the amount of starting material was not a critical issue, but the measurement time
was the limiting factor. In total, 259 individual LC-MS/MS runs were performed in the
course of this project. It resulted in a non-comprehensive data set which yielded several
clues with respect to early actions of TCDD. Based on this information, more targeted
(hypothesis-driven) studies can now be conducted.
4.1.3 Enrichment of phosphopeptides
The calculation of the enrichment efficiency of phosphorylated peptides is a common way
to evaluate the success of the approach. The efficiency is calculated by dividing the num-
ber of identified phosphopeptides by the total number of identified peptides. Based on
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this calculation, the enrichment strategy with SIMAC, HILIC and TiO2 yielded an av-
erage enrichment efficiency of about 70%. A benefit of the enrichment approaches used
was the separation of mono- from multiphosphorylated peptides by the SIMAC method.
However, for the 5L cell lysate, the method was not as efficient as had been expected. Only
14% of all identified phosphorylated peptides were multiphosphorylated. This number was
just slightly higher than the numbers obtained in other studies that did not attempt to
specifically enrich multiphosphorylated peptides [Tweedie-Cullen et al., 2009]. For further
experiments, therefore, SIMAC needs to be optimized for use with 5L cells in order to enrich
more multiphosphorylated peptides. Following SIMAC, the sample was pre-fractionated
on a TSK-HILIC column. This technique proved highly suitable for the pre-fractionation
of the phosphopeptides, the overlap of individual peptides between different fractions being
only ∼20%. Moreover, sample loading and elution occur under salt-free conditions which
obviates the need for additional desalting steps prior the following sample processing steps.
The phosphopeptide enrichment efficiency of HILIC in combination with IMAC has been
shown superior to that of SCX in combination with IMAC [McNulty and Annan, 2008].
However, since HILIC as a standalone enrichment method is not efficient enough, an ad-
ditional specific enrichment step is necessary. Therefore, a further enrichment with TiO2
was performed. TiO2 is easy to apply and has turned out to be very efficient.
4.1.4 Statistics
In the field of proteomics, various strategies are available to define differentially regulated
peptides or proteins. The most common method is based on the determination of the
”fold-change”. The fold-change parameter displays the ratio between the treated and the
control samples [Andersen et al., 2009]. A 1.5- or 2-fold change is a typical threshold for
the definition of regulated peptides. A drawback of the fold-change cut-off is that the
variability between biological replicates is not taken into account and reproducibility is not
guaranteed [McCarthy and Smyth, 2009]. During the last few years which saw the publica-
tion of numerous proteomic studies reporting the identification of continuously increasing
numbers of proteins and peptides it became more and more obvious that it is important to
apply statistical tests in order to obtain more confident results. For this study, an empirical
Bayes moderated t-test together with the q-value for the FDR calculation was used. The
moderated t-test can be used for studies with only few replicates [Smyth, 2005] and for
this reason was ideal for the analysis of the data sets presented here. The q-value, which is
getting more and more important in the proteomics area, was calculated to narrow the frac-
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tion of false positive hypotheses (adjustment of the p-values) [Sachs and Hedderich, 2009].
This method is less conservative than the very common Bonferroni method. The q-value
adjustment avoids a rejection of true differential phosphorylation events. The combination
of the empirical Bayes moderated t-test with the q-value approach was a good strategy
to achieve reliable results. However, for the p- and q-value calculation several replicates
are required and with increasing numbers of replicates the statistical power increases. In
contrast, the FC method can be applied to single runs, which is particularly interesting
for e.g. clinical samples where only a limited amount of sample material is available and
running replicates is impossible. Another problem associated with the statistical tests is
the lack of good software. The major part of the available software covers only very few
statistical functions. One exception is the statistics platform R [Gentleman et al., 2004a]
in combination with Bioconductor [Gentleman et al., 2004b] which offers a great variety
of options to the user. Due to a missing graphical user interface it is, however, not very
user-friendly.
4.1.5 Reproducibility
Only peptides found in at least two biological replicates where taken for the p-value cal-
culation. The overlaps between the biological replicates were relatively low. In Figure 4.1
the Venn Diagrams for the 30-min and the 2-h exposures to DMSO/TCDD are shown.
A substantial number of the identified phosphorylated proteins were observed in
one replicate only. This observation was not surprising. Variations of identified pro-
teins/peptides between datasets are a common problem in large-scale proteomics studies
and a much-debated topic [Aittokallio, 2010]. Durr et al. found that only 66% of the pro-
teins identified in one LC-MS/MS run were confirmed when the same sample was injected
a second time into the mass spectrometer [Durr et al., 2004]. After ten measurements,
only 5 newly identified proteins were not confirmed by the nine other measurements. This
clearly shows a great technical variance.
Incomplete datasets due to missing values can be caused by biological differences and
technical bias. To increase reproducibility, different biological replicates can be pooled
together during sample preparation and the sample can be measured several times.
Before data analysis, the missing values have to be removed or predicted as accurately
as possible. A non-optimal solution is to fill up the missing values with zeros or the average
values [Albrecht et al., 2010]. However, this method does not take into account the biases
from the data sets. Different mathematical models were developed to overcome the problem
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(a) Venn Diagram Biological Replicates 30 min (b) Venn Diagram Biological Replicates 1 hours
(c) Venn Diagram Biological Replicates 2 hours
Figure 4.1: Venn diagrams for 30 min, 1 and 2 hours samples. Dia-
grams show the overlap of the identified phosphorylated peptides between the bi-
ological replicates. (a) (b) (c) The diagrams were created with program Venny
(http://bioinfogp.cnb.csic.es/tools/venny/index.html)
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of the missing values. The k-nearest-neighbour imputing (KNN) was introduced in 2001
and originally used for the analysis of microarray data [Troyanskaya et al., 2001]. This
approach has been also applied to LC-MS-based proteomics data [Roxas and Li, 2008].
The missing value from one data set is imputed by the weighted mean of available values
of the k most related proteins/peptides in this set [Albrecht et al., 2010]. However, to apply
this approach, a certain minimal number of biological experiments have to be performed.
For the present project, mainly three biological replicates were analysed. This number of
replicates is not sufficient for missing value calculations. Therefore, the peptides identified
only once within the replicates were not subjected to a statistical test.
4.2 The identified TCDD-induced alterations in pro-
tein phosphorylation
Changes in protein phosphorylation by TCDD which occur before the alteration of protein
expression may occur as the consequence of different mechanisms. These include i) the
activation of signalling pathways preceding and required for the binding of the liganded
AhR/ARNT heteromer to the DRE [Monteiro et al., 2008], [Lin et al., 2008], ii) activa-
tion or inactivation of transcriptional regulators accompanying or following the binding
of the liganded AhR/ARNT heteromer to the DRE and the activation of transcription
[Beischlag et al., 2008] as well as iii) the activation of other signalling pathways not re-
quired for the transcriptional activation of target genes of TCDD [Matsumura, 2009]. The
first (i) and the third (iii) group of events are generally regarded as nongenomic responses.
In the Discussion, the identified alterations in protein phosphorylation will be discussed
with respect to the nature of the affected proteins and, whenever possible, the potential
functional consequences of the phosphorylation change. In many cases, a meaningful in-
terpretation of the obtained findings appeared difficult or was virtually impossible as the
majority of the identified phosphorylation sites affected by TCDD were novel, i.e. had
not been known for the particular protein in any species. In other cases, they had been
reported already, but were not associated with any information of their function thus pre-
cluding an assessment of the functional consequences of the alteration. Moreover, several
of the peptides exhibiting TCDD-induced phosphorylation changes were observed in only
one of the experiments performed, probably as a consequence of the undersampling prob-
lem associated with the limited MS/MS scan speed in the LC-MS/MS analysis of highly
complex peptide mixtures. Clearly, these phosphorylation changes will require independent
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experimental confirmation, e.g. by Selected Reaction Monitoring which would allow the
targeted quantitative analysis of specified phosphopeptides. However, in view of the high
precision of the SILAC approach which allows the side-by-side quantitation of peptides
derived from different samples it is considered that the phosphorylation changes of the
majority of these ”one hit peptides” which exhibited a regulation factor of ≥ 1.5 actually
indicate a true effect of TCDD that will be reproduced in further in-depth studies. They
will, therefore, also be discussed herein whenever it appears useful for the understanding
of certain activities of TCDD in the cells.
4.2.1 Proteins previously associated with nongenomic actions of
TCDD
Mitogen-activated protein kinase 14 (p38alpha/ Mapk14 )
Previous to the present work, the transcription-independent increased phosphorylation of
the Mitogen-activated protein kinase 14 by TCDD observed by Weiss et al. (2005) was
the only phosphorylation change reported to occur in 5L cells during short exposures
(1-2 hours) to TCDD [Weiss et al., 2005]. This finding has been confirmed here by the
observation of a significant up-regulation of the Tyr182 phosphorylated form of p38alpha,
also known as Mitogen-activated protein kinase 14 (MAPK 14), by a factor of ∼1.6 in one
of the two experiments with 2 h TCDD exposure (Table 3.8, No. 1). Activation of MAPK
14 occurs by simultaneous phosphorylation of Tyr182 and Thr180 by upstream kinases.
After 1 h exposure to TCDD, both phosphorylations were found up-regulated by a factor
of 1.41 in one of the experiments (Table 3.8, No. 1). Although this factor was below the
threshold of 1.5 regarded as significant in the present study, the fact that the increases
were identical for both phosphorylation sites strongly suggests that they actually reflected
an early activation of MAPK 14 in the presence of TCDD. In two of the 1 h experiments,
a peptide containing the phosphorylated Ser residue of MAPK 14 (pSQERPTFYR) was
observed without any indication of a TCDD-dependent regulation (Table 8, Appendix).
An observation in accord with the finding of Weiss et al. [Weiss et al., 2005] that the
protein level of p38 in 5L cells is not affected by TCDD treatment.
Other proteins previously associated with nongenomic actions of TCDD
Remarkably, no TCDD-induced phosphorylation changes associated with nongenomic ac-
tions of TCDD reported for certain other cell systems, such as activation of phospholipase
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A2 and c-Src [Matsumura, 2009], were observed. This may be due to the limited resolving
power of the mass spectrometric method used for the analysis of the highly complex pro-
tein samples. It could, however, also reflect certain specific features discriminating the 5L
cells from other cells used in earlier studies on nongenomic effects of TCDD. Thus, prelimi-
nary studies aiming at the detection of increases in Tyr419 phosphorylation or decreases in
Tyr530 phosphorylation as indicators of c-Src activation [Thomas and Brugge, 1997] did
not provide any evidence for an alteration of c-Src activity by TCDD in 5L cells, and cy-
clooxygenase 2 induction, which has been associated with c-Src activation, does not occur
in these cells (U. Andrae, personal communication). It appears possible that the absence
of these nongenomic effects of TCDD is a consequence of the recently discovered fact that a
functional EGF receptor, which has been implicated in these nongenomic actions of TCDD
[Dong and Matsumura, 2008], is lacking in 5L cells (U. Andrae, personal communication).
4.2.2 AhR (Ahr) and ARNT (Arnt)
In the present study, evidence was obtained for TCDD-induced phosphorylation changes
of both partners of the AhR/ARNT heterodimer, although at different levels of certainty.
For the AhR, in one of the 30-min experiments a peptide phosphorylated at two closely
spaced sites (Tyr412/Ser415) was identified that was down-regulated by a factor of 0.68
(Table 3.8, No. 2), a value just above the FC threshold of 1.5. It appears that this phos-
phorylation of the AhR has not been described before. The phosphorylation site is located
C-terminal of the PAC (PAS-associated C-terminal) domain of the AhR (residues 346-384)
and might thus affect the contribution of PAC to the PER-ARNT-SIM 2 (PAS 2) domain
[Hefti et al., 2004] of the receptor. It remains to be confirmed that the Tyr412/Ser415
phosphorylation is actually down-regulated by TCDD and, if this turns out to be the case,
to be determined whether it is involved in the activation of the AhR by TCDD.
A clear result was obtained for the AhR heterodimerization partner ARNT, for which
2.4 and 3.7-fold increases in the phosphorylation of its Ser77 residue in TCDD-exposed cells
were observed in two experiments for the 1 h and the 2 h time points, respectively(Table 3.8,
No. 3). Ser77 phosphorylation of ARNT has been tentatively associated with the targeting
of ARNT dimers to different enhancers [Kewley and Whitelaw, 2005]. In addition to form-
ing active heterodimeric complexes with AhR which bind to DREs within dioxin-responsive
enhancers and thereby mediate transcriptional activation of genes of the AhR gene battery,
the homodimers of ARNT have been shown to bind to a palindromic enhancer sequence 5’
CACGTG-3’ termed ”E-box element” [Sogawa et al., 1995], [Huffman et al., 2001], a se-
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quence not recognized by the AhR/ARNT heterodimer [Whitelaw et al., 1993]. Interest-
ingly, in vitro phosphorylation of Ser77 of ARNT by casein kinase II (CKII) was shown to
result in decreased binding by ARNT homodimers to an E-box element probe and decreased
the activation of an E-box reporter gene in 293T cells whereas binding of the ARNT/AhR
heterodimer to the DRE was not affected [Kewley and Whitelaw, 2005]. These observa-
tions indicated that Ser77 phosphorylation regulates ARNT DNA binding and gene activa-
tion, but it remained open to question whether Ser77 phosphorylation also occurs in vivo
and how phosphorylation might be controlled. The present results for the first time show
that phosphorylation of Ser77 of ARNT indeed occurs in vivo and that TCDD up-regulates
this phosphorylation. It thus appears likely that TCDD inhibits binding of ARNT homod-
imers to the E-box element, and this inhibition may increase the availability of ARNT for
dimerization with the Ah receptor, binding to DREs and activation of dioxin-responsive
genes. In accordance with the observations of Kewley and Whitelaw (2005), an in silico
search using the Group-based Prediction System (GPS) v2.1.1 software, a tool for predict-
ing protein phosphorylation sites and their cognate kinases [Xue et al., 2008], suggested
CKIIa/b, but no other kinase, to be involved in the Ser77 phosphorylation of ARNT (not
shown). These data suggest that CKII is involved in TCDD-induced nongenomic phos-
phorylation events upstream of DNA binding of the AhR/ARNT heterodimer and that it
promotes AhR/ARNT binding to the DRE.
4.2.3 Regulators of the transcriptional machinery involved in
AhR/ARNT-mediated gene activation
Transcriptional activation of dioxin-responsive genes by the liganded AhR/ARNT het-
erodimer can be differentiated into the assembly of a pre-initiation complex at the pro-
moters of TCDD-responsive genes, chromatin remodelling over the promoter, initiation of
transcription and transcript elongation. It had been expected that the present study would
identify TCDD-induced alterations of proteins involved in these processes, and it turned
out that this was actually the case.
Transcription intermediary factor 1-beta (TIF1β/ Trim28 )
Transcription intermediary factor 1-beta (TIF1β), also known as KRAB-associated pro-
tein 1 or Nuclear corepressor KAP-1, is an epigenetic regulator of transcription involved in
the control of chromatin remodelling. TIF1β showed an up-regulation of its Ser474 phos-
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phorylation by a factor of 1.58 in one of the 30-min experiments and a highly significant
up-regulation in two of the experiments with 2 h exposure to TCDD (Table 3.8, No. 4).
Phosphorylation of Ser474 has not yet been described for the rat protein but has been
observed in numerous studies for the corresponding Ser473 residue of the human ortholog,
i.e. [Beausoleil et al., 2004], [Kim et al., 2005], [Olsen et al., 2006]. TIF1β functions as
the universal corepressor for the Krüppel-associated box (KRAB) domain-containing zinc
finger protein superfamily of transcriptional repressors [Abrink et al., 2001]. Physical in-
teraction between TIF1-beta and these zinc finger proteins occurs through a conserved in-
teraction between variants of the KRAB domain and TIF1β. The KRAB-TIF1β complex
recruits members of the heterochromatin protein 1 (HP1) family as well as other chromatin
modification factors to specific loci and thereby causes the formation of heterochromatin-
like complexes and gene silencing. Chang et al. (2008) recently reported that the formation
of the TIF1β-HP1beta complex is regulated by the phosphorylation of TIF1β at Ser473, a
residue conserved between man and mouse and corresponding to Ser474 of the rat ortholog
[Chang et al., 2008]. These residues are located closely to the HP1-box (amino acids 477-
514 for the rat protein). This phosphorylation is dynamically associated with cell cycle
progression and functionally linked to transcriptional regulation. Chang et al. showed that
target genes of TIF1β are cyclin A2, the cell cycle regulators cyclin-dependent kinase 1
(Cdc2 /CDK1) and Cdc25a. Expression of these genes should therefore potentially be en-
hanced by TCDD. Interestingly , TCDD actually increases cyclin A protein level in the rat
liver oval cell line WB-F344 [Dietrich et al., 2002], [Weiss et al., 2008] and the dog kidney
epithelial cell line MDCK [Weiss et al., 2008]. In WB-F344 cells the increase in cyclin A
protein was associated with a release from contact inhibition. The stimulation of cyclin A
expression was attributed to an AhR-dependent, but probably ARNT-independent, induc-
tion of the AP-1 transcription factor jun-D which resulted in transcriptional up-regulation
of cyclin A expression and thereby deregulation of cell cycle control. In 5L cells, TCDD
inhibits proliferation, even though Ser474 phosphorylation of TIF1β is up-regulated, and
cyclin A is not induced, probably as a consequence of a lack of jun-D induction in these
cells [Weiss et al., 2008].
In one of the 30-min experiments, the TIF1β target gene and binding partner of cyclin
A, Cdc2 /CDK1, exhibited an increased phosphorylation of its Tyr15 residue (3.8, No.
5), a phosphorylation that has been associated with the inactivation of the enzyme and
inhibition of cell cycle progression [Ferrari, 2006]. This observation appears consistent with
the induction of the G1/S cell cycle block consistently observed in TCDD-exposed 5L cells
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although this block, which has been attributed to the induction of the cyclin-dependent
kinase inhibitor p27/Kip1 [Kolluri et al., 1999], does not become manifest until a few hours
later [Göttlicher et al., 1990], [Sarioglu et al., 2006].
Moreover, in one of the 2-h experiments, a down-regulation of Ser33 phosphorylation
of the RNA binding protein ”RNA-binding motif, single-stranded-interacting protein 2”
(Rbms2 )was observed (Table 3.8, No. 6). Almost no information is available on the
rat protein, but for the human ortholog, which is also known as ”Suppressor of CDC2
with RNA-binding motif 3” (SCR3), evidence has been obtained that it may be involved
in the regulation of Cdc2 /CDK1 translation [Kanaoka and Nojima, 1994]. The potential
implications of these phosphorylation changes of Cdc2 /CDK1 and RNA-binding motif,
single-stranded-interacting protein 2, which clearly require experimental confirmation, for
the function of Cdc2 /CDK1 in TCDD-exposed cells remain to be determined.
RD RNA binding protein (Rdbp protein/ Rdbp)
A further interaction partner of TIF1β with TCDD-altered phosphorylation detected in
the present study was the protein ”RD RNA binding protein”, the ortholog of the human
protein ”Negative elongation factor E” (NELF-E) or ”RD RNA binding protein”. The
protein exhibited a regulation factor of its Ser115 phosphorylation of 1.12 in one of the
experiments with 30 min TCDD exposure and highly significant increases at both 1 and 2
hours (Table 3.8, No. 7a). In addition, Ser51 phosphorylation was increased in one exper-
iment each at the latter time points (Table 3.8, No. 7b). Western blotting experiments
showed that these up-regulations were not due to TCDD-induced increases in total protein
levels.
The phosphorylation of these serine residues had not been described before
for the rat but observed in several large scale phosphoproteomics studies for
the human ortholog NELF-E for both Ser115 and Ser51 [Beausoleil et al., 2004],
[Olsen et al., 2006], [Wang et al., 2008], [Gauci et al., 2009], [Oppermann et al., 2009])
and Ser51 [Imami et al., 2008], [Mayya et al., 2009]. NELF-E is an essential compo-
nent of a complex known as ”negative elongation factor” (NELF) which is involved
in the regulation of transcript elongation by RNA polymerase II during transcription,
an important target of mechanisms regulating gene expression in response to exoge-
nous stimuli [Peterlin and Price, 2006]. Shortly after initiation, NELF acts in concert
with another negative transcription elongation factor, the ”DRB (5,6-dichloro-1-beta-D-
ribofuranosylbenzimidazole)-sensitivity inducing factor” (DSIF), to repress transcript elon-
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gation by trapping the elongation complex near the promoter, a process referred to as
”promoter-proximal pausing”. This NELF-induced transcription suppression has been
proposed to provide a window of time for proper coordination of transcript processing
[Fujinaga et al., 2004]. Knockdown of NELF-E resulted in a 3- to 4-fold increase of AhR
mRNA expression indicating a role of the NELF complex in the negative regulation of
the expression of a basic component of the AhR signalling pathway [Narita et al., 2007].
Phosphorylation of DSIF and NELF-E by the ”positive transcription elongation factor b”
(P-TEFb) kinase complex transforms DSIF into a positive elongation factor and releases
NELF from the RNA thereby reversing the NELF/DSIF-induced transcriptional pausing
and initiating transcript elongation. Serine residues 181, 185, 187, and 191 of NELF-E,
which are located N-terminal to its RNA recognition motif domain (positions 247 to 342),
have been identified as targets for phosphorylation by P-TEFb [Fujinaga et al., 2004]. In-
terestingly, P-TEFb has been shown to physically interact with the TCDD-liganded AhR
which binds to the cyclinT subunit of P-TEFb and recruits P-TEFb to the cyp1A1 pro-
moter [Tian et al., 2003] resulting in the phosphorylation of the C-terminal domain of RNA
polymerase II to enable transcript elongation.
The present results now show that Ser51 and Ser115 phosphorylation of the rat ho-
mologue of NELF-E can be modulated by exogenous factors. They further suggest that
increases in the phosphorylation of these sites by an unknown kinase may contribute to the
positive regulation of transcription elongation of AhR target genes by the TCDD-liganded
AhR. At present, there are only few mammalian genes for which a regulation by a NELF-
mediated transcriptional pausing mechanism has been clearly established. These include
the early immediate genes c-fos, tis-11 and junB suggesting an important role of NELF in
the regulation of a subset of inducible genes [Aida et al., 2006]. That TCDD positively af-
fects the expression of early immediate genes expression has been shown, among others, for
Hepa-1 mouse hepatoma cells, where TCDD increased the mRNA levels for c-fos and junB
as well as for c-jun and junD [Puga et al., 1992], [Hoffer et al., 1996]. In 5L cells, TCDD
stimulated the expression of c-jun mRNA and protein [Weiss et al., 2005]. In the present
study, the NELF-E- regulated immediate early gene product ”Butyrate response factor 1”
(also known as Zinc finger protein 36, C3H1 type-like 1, Zfp36l1 ), a further nucleic acid
binding protein, was one of the proteins with elevated phosphorylation at 60 min in one
experiment (Table 3.8, No. 8). Since no further phosphorylated or non-phosphorylated
peptide was identified it remained open to question whether this up-regulation was caused
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by an increased expression of this early immediate gene or by a specific stimulation of its
Ser54 phosphorylation which had been observed before [Moser and White, 2006].
It also appears possible that the increase in NELF-E phosphorylation by TCDD con-
tributes to an enhanced mRNA processing of TCDD-regulated genes as NELF is also in-
volved in 3’ end transcript processing [Narita et al., 2007]. Intriguingly, NELF-E, but none
of the other NELF subunits, has been reported to bind to CBP80, a subunit of the nuclear
cap binding complex (CBC), another RNA binding protein complex [Narita et al., 2007].
CBP80 is the human ortholog of ”Nuclear cap-binding protein subunit 1” (Ncbp1 ), a pro-
tein identified in one of the 2 h experiments to exhibit a doubling of phosphorylation at
Ser7 following TCCD exposure of the cells (Table 3.8, No. 9). The Ser7 residue is lo-
cated within the bipartite nuclear localization signal of CBP80 and its phosphorylation
may thus promote its translocation to the nucleus. It has been shown that NELF and
CBC function together in the 3’ end processing of histone mRNAs and, probably, other
types of RNA. Knockdown of CBP80 resulted in a decrease of ARNT mRNA expression
by ∼50%, implicating both the functional NELF holocomplex and its interaction partner
CBC in the regulation of the expression of basic components of the AHR signalling path-
way [Narita et al., 2007]. The observation of the simultaneous up-regulation of specific
phosphorylations of the two directly interacting proteins NELF-E and CBP80 by TCDD
supports the assumption that TCDD modulates RNA synthesis and transcript processing
by interfering with the phosphorylation of specific components of the NELF and the CBC
complexes.
Mediator of RNA polymerase II transcription subunit 24 (Thyroid hormone
receptor associated protein 4, isoform CRA a/ Med24 )
A further novel observation on the interaction of TCDD with the transcription machinery
is the increased phosphorylation at Ser879 of the protein ”Mediator of RNA polymerase
II transcription subunit 24” (Med24 ) or ”Thyroid hormone receptor associated protein 4,
isoform CRA a” (Table 3.8, No. 10). This protein is a component of the so-called ”Media-
tor of RNA polymerase II complex” (”Mediator”). Mediator is a multisubunit coactivator
complex involved in the regulation of gene expression of nearly all RNA polymerase II-
dependent genes. It also conveys information from sequence-specific bound transcriptional
activators and repressors to the RNA polymerase II (PolII) pre-initiation complex in the
regulated transcription of specific genes [Conaway et al., 2005]. Intriguingly, Wang et al.
(2004) showed that the Mediator complex physically associates with the ligand-bound AhR
85
CHAPTER 4. DISCUSSION
and MED220 (a subunit of the Mediator complex). The complex is recruited to the en-
hancer of the CYP1A1 gen, but not to the promoter [Wang et al., 2004]. Our present
results suggest that the TCDD-induced interaction between the Mediator complex and the
AhR is accompanied by the phosphorylation of ”Thyroid hormone receptor associated pro-
tein 4” at Ser879, but the relation between ”Thyroid hormone receptor associated protein
4” phosphorylation and Mediator recruitment is still currently unclear. It appears likely,
however, that this phosphorylation is involved in the stimulation of AhR/ARNT-mediated
gene expression by TCDD.
Ataxin-2 (ATXN2/Atxn2)
A further transcriptional regulator exhibiting a TCDD-induced phosphorylation change
was Ataxin-2 for which the down-regulation of a peptide doubly phosphorylated at two
closely spaced serine residues, Ser511 and 515, by a factor of ∼0.6 was observed in one of
the experiments with 2 hours TCDD exposure (Table 3.8, No. 11). Recently, it has been
shown that Ataxin-2 acts as a co-regulator of a KRAB-containing zinc-finger transcriptional
regulator known as ”BRCA1-interacting protein with a KRAB domain 1” and that the
interaction of the two proteins results in the activation of the transcription of the sca2
gene [Hallen et al., 2011]. In addition to its function as a transcriptional co-regulator, the
gene product of Atxn2 appears to function in RNA metabolism and endocytosis. The
functional relevance of the Ser511/515 phosphorylation, which had not been described so
far, is still unclear.
4.2.4 Regulators of small GTPases of the Ras superfamily
An unexpected outcome of the present study was the presence of six proteins functionally
involved in signalling events mediated by small GTPases of the Ras superfamily within the
group of proteins with TCDD-altered phosphorylation. These GTPases can occur in an
active GTP-bound form and an inactive GDP-bound form and their activity is controlled
by a variety of activating guanine nucleotide exchange factors (GEFs) which exchange GDP
by GTP, and GTPase-activating proteins (GAPs) which promote the inactivation of the
protein by GTP hydrolysis [Geyer and Wittinghofer, 1997]. In their active states, small
GTPases bind to a plethora of downstream effector proteins to regulate cellular responses.
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Regulators of Rho GTPases
The identified proteins include three effectors of GTPases of the Rho family (Pragmin, Src
homology 3 domain-containing guanine nucleotide exchange factor (Sgef ) and Cdc42 effec-
tor protein 1 (Cdc42ep1 )). Rho GTPases play key roles in cytoskeletal dynamics and regu-
late a wide range of morphogenetic events, such as cell adhesion, cell migration, cell spread-
ing, vesicle trafficking, cytokinesis and endocytosis [Etienne-Manneville and Hall, 2002].
They can also control many other functions, such as cell-cycle progression and gene ex-
pression.
Pragmin (Pragmin)
Pragmin (”pragma of Rho family GTPase 2”) exhibited a statistically significant down-
regulation of its phosphorylation at Tyr391 after 1 h of TCDD exposure (Table 3.8, No.
12). The protein is a specific effector protein of Rho family GTPase 2, a member of the
Rnd subfamily of Rho GTPases which has been implicated in the reorganisation of the
actin cytoskeleton and subsequent morphological changes in various cells. The human
ortholog of Pragmin is termed Tyrosine-protein kinase SgK223. SgK223 was identified as
a Src substrate in metastatic human SW620 colorectal carcinoma cells [Leroy et al., 2009]
and furthermore it has been reported, Pragmin was phosphorylated by Src at Tyr391,
the observed phosphorylation site affected by TCDD in the present study. Expression
of Pragmin Y391F, in which the tyrosine was replaced by phenylalanine, had a reduced
rescuing effect on invasiveness in cells with reduced SgK223 implicating phosphorylation
of Tyr391 in invasive signalling [Leroy et al., 2009]. This function of the gene product of
Pragmin is consistent with the reorganisation of the actin cytoskeleton for which strong
evidence had been obtained in previous quantitative proteomic studies on 5L cells exposed
to TCCD [Sarioglu et al., 2006], [Sarioglu et al., 2008]. Preliminary studies on 5L cells did
not provide evidence for an alteration of Src activity by TCDD (see below) suggesting
that the observed down-regulation of Tyr391 phosphorylation of Pragmin is mediated by
another mechanism.
Similar to Src homology 3 domain-containing guanine nucleotide exchange fac-
tor (Sgef )
The protein ”Similar to Src homology 3 domain-containing guanine nucleotide exchange
factor” (Sgef ) exhibited significantly decreased phosphorylation of its serine residue 390
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by a factor of ∼0.6 in the 2-h experiments (Table 3.8, No. 13). This phosphorylation site
corresponds to Ser392, one of two known phosphorylation sites identified for the human
ortholog known as Rho guanine nucleotide exchange factor 26 [Mayya et al., 2009]. This
protein has been shown to be a GEF involved in the regulation of Rho protein signal trans-
duction [Qi et al., 2003]. It specifically activates RhoG GTPase [Ellerbroek et al., 2004],
an upstream regulator of other Rho GTPases. Rho guanine nucleotide exchange factor 26
is known to be required for actin remodelling and the formation of membrane ruffles dur-
ing macropinocytosis [Ellerbroek et al., 2004], which in most cells is transient and occurs
downstream of growth factor receptor activation.
At present there is no information on the functional role of the Ser390 phosphorylation.
This phosphorylation site is located relatively close to the N-terminal end of the Dbl-
homologous (DH) domain (residues 438-619, NCBI Reference Sequence XP 227201.4), the
conserved catalytic core of most Rho GEF proteins, and the conservation of this phospho-
rylation site in the rat and human sequences suggests that it is important for the activity
of the protein.
Cdc42 effector protein 1 (Cdc42ep1 )
Cdc42 effector protein 1 (Cdc42ep1 ), also known as Binder of Rho GTPases 5, exhibited
a down-regulation of its Ser193 phosphorylation by a factor of ∼0.6 at 2 h in one exper-
iment (Table 3.8, No. 14). Whereas nothing is known about the rat protein, the human
ortholog has been shown to be an effector protein of the product of the CDC42 gene,
Cell division control protein 42 homolog, a plasma membrane-associated small GTPase
[Joberty et al., 1999], [Burbelo et al., 1999]. Cdc42 effector protein 1 was suggested to
function as a negative regulator of Rho GTPase signalling and to affect the organization of
the actin cytoskeleton at the plasma membrane resulting in an inhibition of cell spreading
[Joberty et al., 1999]. At present, nothing is known about the functional consequences of
Ser193 phosphorylation of Cdc42 effector protein 1 of the rat.
Regulators of Rab GTPases
The altered phosphorylation-containing regulators of the activity of small GTPases also
included three proteins involved in the regulation of Rab GTPase family members, namely
Hematological and neurological expressed 1 protein, DENN/MADD domain containing
5A, and Rab GTPase activating protein 1. Rab familiy GTPases are recognized as premier
88
4.2. THE IDENTIFIED TCDD-INDUCED ALTERATIONS IN PROTEIN
PHOSPHORYLATION
organizers of intracellular transport and membrane trafficking pathways in eukaryotic cells
[Zerial and McBride, 2001].
Hematological and neurological expressed 1 protein (Hn1 )
The protein ”Hematological and neurological expressed 1 protein” (Hn1 ) was found to show
a significantly increased phosphorylation of its Ser82 residue by a factor of ∼1.5 after 2 h of
TCDD exposure (Table 3.8, No. 15). This phosphorylation of the rat protein has not yet
been reported, but that of the corresponding site in the human ortholog, Ser87, has been ob-
served in several studies [Imami et al., 2008], [Zahedi et al., 2008], [Dephoure et al., 2008],
[Zougman and Wísniewski, 2006], [Mayya et al., 2009]. The gene product of (Hn1 ) is
highly conserved among species and widely expressed in numerous tissues during embryonic
development [Zhou et al., 2004] and tissue regeneration [Zujovic et al., 2005]. Laughlin et
al. (2009) observed an increased association of the small GTPase Ras-related protein
Rab-27A with actin as a consequence of the knockdown of Hematological and neurological
expressed 1 protein indicating an effect of this protein on cytoskeleton-associated func-
tions [Laughlin et al., 2009]. In comparative microarray analyses of human normal ovar-
ian surface epithelial tissue and ovarian carcinoma, it was identified as one of four genes
whose expression perfectly distinguished tumor samples from normal ones [Lu et al., 2004].
Laughlin et al. (2009) also reported that in mouse melanoma cells, knock down of the ex-
pression of the protein resulted in a suppression of cell proliferation as evidenced by a G1/S
cell cycle arrest. Although the precise function of the protein is unknown, these observa-
tions collectively point to a role in promoting growth and maintaining an undifferentiated
or dedifferentiated state for cell development and repair. The functional importance of the
Ser82 phosphorylation is still unknown, but it may be related to TCDD-induced alterations
in cell cycle regulation or cytoskeleton remodelling.
DENN/MADD domain containing 5A (Dennd5a protein/ Dennd5a)
The protein ”DENN/MADD domain containing 5A” (Dennd5a protein/ Dennd5a) was
identified to exhibit an up-regulated Ser193 phosphorylation in one of the experiments
with 1 h exposure to TCDD (Table 3.8, No. 16). Studies on the mouse homolog
identified this protein as a binding partner of the GTP-bound small GTPase Rab-6
[Janoueix-Lerosey et al., 1995] on Golgi membranes [Miserey-Lenkei et al., 2007]. By re-
cruiting various effectors, Rab-6 GTPase regulates vesicle trafficking at the level of the
Golgi apparatus. DENN/MADD domain containing 5A also binds to active Rab11 sug-
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gesting that it coordinates the functions of Rab-6 and Rab-11 in retrograde transport
events between the Golgi complex and recycling endosomes and possibly at mitosis and
during cytokinesis.
The phosphorylation of Ser193 had not yet been reported for the rat protein but for the
human ortholog which is also known as rab6-interacting protein 1. It constitutes the only
posttranslational modification of this protein described so far [Dephoure et al., 2008]. The
functional importance of this phosphorylation is unknown and it remains to be determined
whether TCDD affects Rab-6/Rab-11 interaction.
Rab GTPase activating protein 1 (Rabgap1 )
RAB GTPase activating protein 1 (Rabgap1 ) was a further direct interactor of Rab-6 with a
phosphorylation change in TCDD-exposed cells. It exhibited a down-regulation of its Thr38
phosphorylation by a factor of ∼0.5 in one of the experiments with 2 h exposure (Table
3.8, No. 17). For the human orthologue of this protein, evidence has been obtained that it
acts as a GTPase-activating protein (GAP) of the two known Rab-6 isoforms Rab-6A and
Rab-6A’ which differ by only three amino acids [Echard et al., 2000] and that it plays a role
in microtubule nucleation by the centrosome [Cuif et al., 1999]. Rab GTPase activating
protein 1 has been also suggested to specifically act as an effector of Rab-6A’ and thereby
to participate in a Rab-6A’-mediated pathway required for metaphase-anaphase transition
during mitosis [Miserey-Lenkei et al., 2006]. The Thr38 phosphorylation observed as down-
regulated by TCDD represents a novel phosphorylation site Rab GTPase activating protein
1 with currently no clues with respect to its function.
Taken together, the present observations on the phosphorylation changes of six pro-
teins involved in the regulation of the activity of small GTPases of the Rho and Rab fam-
ilies provide novel evidence that the pronounced effects of TCDD on the actin cytoskele-
ton and actin-associated proteins previously observed in 5L cells [Sarioglu et al., 2006],
[Sarioglu et al., 2008] may be initiated by early alterations of signalling cascades resulting
in altered Rho GTPase signalling rather than by TCDD-elicited alterations in gene ex-
pression. However, since e.g. the Rho family of GTPases also mediates changes in gene
expression and cell division that are independent of the actin cytoskeleton it appears pos-
sible that other, still unknown actions of TCDD may be initiated by an early interference
of TCDD with these GTPases. The upstream events triggered by TCDD and resulting in
the altered phosphorylations of the small GTPase regulators are still unknown.
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4.2.5 UBX domain-containing proteins
The proteins with phosphorylations up-regulated by TCDD also included two members
of the family of ubiquitin regulatory X (UBX) domain-containing proteins, namely UBX
domain-containing protein 4 and an uncharacterised protein predicted to be the product
of the ubxn7 gene, i.e. UBX domain-containing protein 7. UBX proteins, the func-
tions of which are largely unknown, are characterized by the presence of a UBX do-
main that has recently been identified to mediate the binding to the molecular chaperone
p97/valosin-containing protein (VCP), also known as Cell division control protein 48 in
yeast [Alexandru et al., 2008]. p97 is a highly conserved ATPase performing a variety of
functions in all types of cells. It is assumed that it provides the main driving force for the
extraction of misfolded or unassembled proteins in the endoplasmic reticulum (ER) to the
cytoplasm for degradation by the proteasome by the ER-associated protein degradation
(ERAD) pathway [Ye, 2006].
UBX domain-containing protein 4 (Ubxn4 )
UBX domain-containing protein 4, also known as erasin, exhibited an up-regulation of a
hitherto unknown Thr156 phosphorylation that was observed for both the 1-h and the
2-h exposure period (Table 3.8, No. 18). It is a UBX-only protein lacking the ubiquitin-
associated (UBA) domain contained in many other UBX domain-containing proteins and,
thus, the ability to bind ubiquitinated proteins directly [Alexandru et al., 2008]. The ER
membrane-associated UBX domain-containing protein 4 plays a central role in the ERAD
pathway [Lim et al., 2009]. It has been suggested to act as a scaffold ensuring the ordered
transfer of the protein destined for degradation from the ER lumen to the proteasome. The
potential role of the Thr156 phosphorylation which is located in the large N-terminal cyto-
plasmic portion of the protein in this process is unknown, but the observed phosphorylation
change suggests that TCDD might somehow affect ERAD. In this context it is noteworthy
that the ER is also a TCDD target as there is evidence that TCDD activates inositol 1,4,5-
trisphosphate (IP3) receptors in the ER resulting in the release of Ca2+ from the ER into
the cytoplasm and facilitating the downstream activation of AhR receptor target genes
[Monteiro et al., 2008]. Recent studies have shown that the IP3 receptors, which function
as Ca2+ release channels in the ER, are immediately destroyed via the ERAD pathway
following activation in order to reduce the sensitivity of ER Ca2+ stores to IP3 and, prob-
ably, to protect the cells against deleterious effects of over-activation of Ca2+ signalling
pathways [Wojcikiewicz et al., 2009]. Although it is presently pure speculation, it appears
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conceivable that the increase in Thr156 phosphorylation of UBX domain-containing protein
4 by TCDD may be functionally associated with the stimulation of the ERAD-dependent
degradation of IP3 receptors following their activation by TCDD.
UBX domain-containing protein 7 (Ubxn7 )
For UBX domain-containing protein 7, the other UBX protein with altered phosphorylation
identified after TCDD treatment, two splice isoforms had been observed at the mRNA level
for the rat, and the affected phosphorylation which was up-regulated by a factor of ∼1.9
in one of the 30-min experiments corresponds to Ser267 and Ser289 of the two forms
(Table 3.8, No. 19). For the human ortholog of the protein, this site corresponds to
Ser288 the phosphorylation of which has been identified in several large-scale studies, see
e.g., [Kim et al., 2005]. UBX domain-containing protein 7, like UBX domain-containing
protein 4, has been reported to interact with p97 [Alexandru et al., 2008]. It can directly
associate with ubiquitin conjugates via its UBA domain as well as with the E3 CUL2/VHL
ubiquitin ligase complex and recruit them to p97 for delivery of the ubiquitin conjugate
to the proteasome for degradation [Alexandru et al., 2008] in an ERAD-independent way.
A specific p97/UBX domain-containing protein 7 substrate is hypoxia-inducible factor
1α (HIF1α), the transcriptional key regulator of cellular responses to hypoxia. Under
hypoxic conditions, HIF1α forms a heterodimer with ARNT which binds to an enhancer
termed hypoxia response element (HRE) which mediates the induction of HIF1α target
genes. Activation of AhR/ARNT signalling by TCDD during hypoxia has been shown
to interfere with HIF1α/ARNT gene activation thereby reducing the expression of HIF1α
target genes. Several studies have shown that this negative crosstalk cannot be explained
by a competition of AhR and HIF1α for ARNT [Pollenz et al., 1999], [Tomita et al., 2000].
Intriguingly, TCDD has been reported to cause a AhR-dependent destabilization of HIF1α
protein and proteasomal degradation [Seifert et al., 2008]. The present observation of an
increased phosphorylation of UBX domain-containing protein 7 in TCDD-exposed cells
therefore points to a potential hitherto unknown mechanism linking AhR activation and
p97/UBX domain-containing protein 7-dependent HIF1α degradation.
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4.2.6 Miscellaneous proteins
Protein chibby homolog 1 (Cby1 )
The protein ”protein chibby homolog 1”, also known as ”Chibby” or PIGEA-14, exhibited
a down-regulation of the phosphorylation of its Ser20 residue by a factor of 0.65 in one
of the 2 h experiments (Table 3.8, No. 20). The protein is highly conserved throughout
evolution and has been shown to play a role in regulating the intracellular trafficking of
the calcium permeable cation channel polycystin-2/PKD2 and possibly other intracellular
proteins [Hidaka et al., 2004]. In addition, it acts as an inhibitor of the Wnt/β-catenin
pathway by binding to the transcriptional coactivator β-catenin and inhibiting β-catenin-
mediated transcriptional activation through competition with Tcf/Lef transcription factors
[Takemaru et al., 2003]. In Zebrafish, TCDD has been shown to activate Wnt/β-catenin
signalling by down-regulating the expression of another β-catenin binding inhibitor of
Tcf/Lef activation, SOX-9 [Mathew et al., 2009]. Intriguingly, the Ser20 phosphorylation
of Chibby observed as down-regulated in the present study has been recently identified to
mediate the binding of 14-3-3 proteins to Chibby resulting in cytoplasmic sequestration
of the tripartite 14-3-3 / Chibby / β-catenin complex and inhibition of Wnt signalling
[Li et al., 2008]. Down-regulation of Ser20 phosphorylation which is catalyzed by nuclear-
targeted Akt kinase would therefore be expected to result in increased nuclear localisation
of β-catenin and Wnt signalling activation. It will be interesting to see whether the Chibby
phosphorylation change, which clearly requires confirmation in future experiments, might
be involved in a misregulation of Wnt / β-catenin signalling by TCDD in mammalian cells.
Similar to AHNAK nucleoprotein isoform 1 isoform 2 (Ahnak)
Highly significant increases in phosphorylation were seen after both 1 and 2 h of TCDD
exposure for a serine residue of a protein designated ”similar to AHNAK nucleopro-
tein isoform 1 isoform 2” (Table 3.8, No. 21). The hyperphosphorylated residue corre-
sponded to Ser212 of the human ortholog whose phosphorylation at this site had been
reported already [Moritz et al., 2010]. The fact that the abundance of none of the fur-
ther 26 phosphorylated AHNAK peptides identified in the present study was changed
by TCDD indicates that the up-regulation of Ser212 phosphorylation was not related
to an increase in AHNAK total protein abundance. AHNAK1 is a giant scaffold pro-
tein that is expressed in numerous tissues and established cell lines. It is thought to
play a key role in calcium signalling. It has been reported to interact with intracellular
93
CHAPTER 4. DISCUSSION
regulatory β2 and β1 subunits of L-type voltage-gated calcium channels (Cav1.2 chan-
nels) in cardiomyocytes [Haase et al., 1999], [Hohaus et al., 2002], [Alvarez et al., 2004].
Simultaneous phosphorylation of the C-terminal domain of membrane-associated AH-
NAK1 and the β2 subunit by cAMP-dependent protein kinase A (PKA) in response
to β-adrenoreceptor stimulation has been proposed to result in an increased Ca2+ influx
[Alvarez et al., 2004],[Haase et al., 1999]. Recent studies have shown that AHNAK1 is also
a key element regulating the Ca2+ influx through L-type voltage-gated calcium channels in
nonexcitable cells, such as T cells [Matza et al., 2008], [Matza and Flavell, 2009] and os-
teoblastic cells [Shao et al., 2009]. Moreover, AHNAK has been shown to bind to intracel-
lular Ca2+ binding S100B proteins and annexin 2 and thereby to regulate actin cytoskeleton
organization and cell membrane cytoarchitecture [Benaud et al., 2004]. AHNAK contains
a large number of phosphorylation sites, but besides PKA, only protein kinase B (PKB) has
been identified to be involved in AHNAK phosphorylation [Sussman et al., 2001]. Phos-
phorylation of Ser5335 in the C-terminal domain of human AHNAK by PKB results in
the translocation of AHNAK from the nucleus to the plasma membrane. The simulta-
neous interaction of the central repetitive motifs of AHNAK1 with protein kinase C-α
and phospholipase C-γ1 (PLC γ1) has been shown to cause the activation of PKC which
in turn results in the activation of cPLA2, the formation of arachidonic acid, the con-
certed activation of PLC-γ1 by AHNAK and arachidonic acid and intracellular calcium
mobilization [Sekiya et al., 1999], [Lee et al., 2004], [Lee et al., 2008]. The Ser212 residue
that was found hyperphosphorylated in TCDD-exposed 5L cells and is located in the N-
terminal structural domain. This domain has been predicted to contain a PDZ domain
[Komuro et al., 2004], a specialized protein module believed to interact with C-terminal
peptides of a number of channel proteins, including those involved in calcium transport
[Kim and Sheng, 2004]. The precise function of this PDZ domain as well as that of the
Ser212 phosphorylation is still unknown, but it appears possible that the altered phos-
phorylation of the N-terminal domain may result in altered recruitment of yet unknown
regulators/modifiers of AHNAK activity. In view of the crucial role of AHNAK in the
regulation of Ca2+ entry and signalling in various cell types it was tempting to speculate
that the significant and reproducible increase in Ser212 phosphorylation by TCDD might
be functionally associated with the increase in cytoplasmic Ca2+ concentration by TCDD
[Le Ferrec et al., 2002], [N’Diaye et al., 2006]. However, further experiments showed that
this is unlikely to be the case, since several inhibitors of L-type voltage-gated Ca2+ chan-
nels did not prevent the induction of CYP1A1 protein whereas 2-APB, an inhibitor of
94
4.2. THE IDENTIFIED TCDD-INDUCED ALTERATIONS IN PROTEIN
PHOSPHORYLATION
store-operated Ca2+ channels, completely prevented CYP1A1 up-regulation. Thus, the
functional significance of this phosphorylation and its alteration by TCDD remains to be
determined.
Interferon-inducible double stranded RNA-dependent protein kinase activator
A (Prkra)
”Interferon-inducible double stranded RNA-dependent protein kinase activator A” (Prkra)
exhibited a significant up-regulation of its Ser18 residue in two of the 1-h experiments (Ta-
ble 3.8, No. 22). The protein and its mouse and human orthologs are products of the Rax
and PACT genes, respectively and are regulators of the latent protein kinase R (PKR).
Activation of PRKRA can be caused by cytokines, modification of growth factor supply,
disruption of intracellular Ca2+ homeostasis and oxidative stress, but the nature of the
stress-activated protein kinase(s) involved is still not completely clear. Phosphorylation
of the mouse ortholog of the protein kinase activator at Ser18, a residue conserved be-
tween human, mouse and rat, has recently been shown to be required for PKR activation
and inhibition of translation initiation [Bennett et al., 2004]. In contrast, Ser18 phospho-
rylation was found not essential for the stress-induced activation of the human ortholog
[Peters et al., 2006], and at present it is unknown whether it is essential for the activating
activity of the rat protein and the inhibition of protein synthesis initiation. As Peters et
al. pointed out, it remains possible that different kinds of stresses can activate the enzyme
through phosphorylation of different residues, a paradigm established for the activation
of various transcription factors. Interestingly, inhibition of translation due to interference
with growth factor signalling does occur in TCDD-exposed 5L cells (U. Andrae, personal
communication), but so far this inhibition has been only observed at later time points (≥
6 h) and it remains open to question whether it is related to the increase in Ser18 phospho-
rylation of Interferon-inducible double stranded RNA-dependent protein kinase activator
A.
LYRIC (MTDH/ Mtdh)
The protein LYRIC, also known as metadherin (MTDH) or, in case of the human or-
tholog, ”Astrocyte Elevated Gene 1 protein” (AEG-1), was a further protein which showed
a significant up-regulation of a specific phosphorylation (Ser297) in both experiments with
2 h TCDD exposure (3.8, No. 23). AEG-1 functions as a transforming oncogene that is
overexpressed in all cancers analyzed so far [Emdad et al., 2009] and has been strongly im-
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plicated in the promotion of multiple biochemical and signalling pathways leading to cell
transformation and tumor progession in diverse organs [Sarkar et al., 2009]. The protein
mediates the transforming activity of oncogenic Ha-Ras and c-Myc, and its overexpression
has been shown to activate PI3K/Akt, nuclear factor kappa B (NF-kappa-B), MAP kinase
and Wnt/β-catenin pathways to stimulate cell survival, proliferation, invasion, metastasis,
and angiogenesis. The phosphorylation at Ser297 had not yet been described for the rat but
has been observed in several large-scale phosphoproteomics studies for the mouse protein
[Villen et al., 2007], [Zhou et al., 2008] and the corresponding Ser298 residue of the human
ortholog MTDH/AEG 1 [Olsen et al., 2006], [Dephoure et al., 2008], [Zahedi et al., 2008],
[Gauci et al., 2009], [Mayya et al., 2009]. As for other posttranslational modifications of
LYRIC/AEG-1, it is currently unknown how Ser297 phosphorylation influences the func-
tion of this oncogenic protein [Hu et al., 2009] and what the consequences of the TCDD-
induced up-regulation for the cells might be.
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Conclusions
The present study has identified about 30 proteins exhibiting a statistically significantly
altered phosphorylation in at least two independent experiments for a given time point
or a regulation factor of at least 1.5 in a single experiment following exposure of 5L rat
hepatoma cells to TCDD for 0.5 to 2 hours.
For all of the phosphorylation changes identified, the affected phosphorylation site
within the protein was unambiguously identified. With the exception of the increased
phosphorylation of the MAP kinase p38alpha, none of the phosphorylation changes, which
appear to precede alterations in the expression of AhR/ARNT target genes at the protein
level, had been described before. For a few of the observed alterations, such as the increased
Ser77 phosphorylation of ARNT, the increased Ser474 phosphorylation of TIF1β or the
decreased Ser20 phosphorylation of Chibby, the consequences of the changes appear to be
predictable. However, for the majority of changes the functional importance with respect
to the action of TCDD and the resulting consequences for the dioxin’s toxicity remain to
be elucidated. This is due to the facts that several of the affected phosphorylation sites
have been identified for the first time and that for those phosphorylations that had already
been observed in other studies the functional importance has not yet been investigated.
No TCDD-induced phosphorylation changes associated with nongenomic actions of
TCDD already reported for certain other cell systems were observed. This may be a
consequence of the limited resolving power of the mass spectrometric method used for
the analysis of the highly complex protein samples. It could, however, also reflect certain
specific features discriminating the 5L cells from other cells used in earlier studies on nonge-
nomic effects of TCDD. On the other hand, the study identified phosphorylation changes of
various other proteins, in particular proteins involved in the regulation of transcription as
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well as proteins from other functional classes, such as various regulators of small GTPases
or proteins involved in protein degradation pathways. These proteins or their phosphoryla-
tion changes had not been associated with the action of TCDD previously and they appear
to mediate early, hitherto unknown nongenomic actions of the dioxin. The present study
therefore provides a large number of novel starting points for further detailed investigations
of the signalling events involved in the early actions of TCDD in mammalian cells and the
consequences with respect to the mechanisms underlying the toxicity of dioxins. In future
studies, the resolution capacity of the experimental approach may be enhanced by further
refinement of the experimental protocol, such as the incorporation of cell fractionation
steps, optimization of the phosphopeptide enrichment protocol and the implementation of
ETD fragmentation and gas phase fractionation into the MS analysis step.
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Bardin, S., Piel, M., Racine, V., Sibarita, J.-B., Perez, F., Bornens, M., and Goud,
B. (2006). A role for the rab6a’ gtpase in the inactivation of the mad2-spindle check-
point. EMBO J, 25(2):278–89.
[Miserey-Lenkei et al., 2007] Miserey-Lenkei, S., Waharte, F., Boulet, A., Cuif, M.-H.,
Tenza, D., El Marjou, A., Raposo, G., Salamero, J., Héliot, L., Goud, B., and Monier,
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and Dietrich, C. (2008). Tcdd deregulates contact inhibition in rat liver oval cells via
ah receptor, jund and cyclin a. Oncogene, 27(15):2198–207.
[Weiss et al., 1996] Weiss, C., Kolluri, S. K., Kiefer, F., and Göttlicher, M. (1996). Com-
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Appendix A Tables
The Tables 1, 3 and 5 contain the unique peptides identified in at least two biological
replicates per time point including IPI and Uniprot accession, protein name (Description),
ion score, PTM score, peptide sequence with phosphorylation and other modification as-
signment, gene name, GO ID and description, KEGG ID, REFSEQ accession, ENSEMBL
ID, PFAM accession and ID, the normalized ratio for the different biological replicates and
the corresponding mean as well as the p- and q-values.
The Tables 2, 4 and 6 contain the unique peptides identified in only one biological
replicate per time point including IPI and Uniprot accession, protein name (Description),
ion score, PTM score, peptide sequence with phosphorylation and other modification as-
signment, gene name, GO ID and description, KEGG ID, REFSEQ accession, ENSEMBL
ID, PFAM accession and ID and the normalized ratio.
APPENDIX A. TABLES
Table 1: List of all unique peptides identified in at least two biological replicates
in 5L cells after 30 min treatment with TCDD. A total of 1918 peptides (FDR
p < 1%) including 1383 phosphorylated peptides were identified with an ion score of ≥ 20.
(Table provided on an accompanying CD)
Table 2: List of all unique peptides identified in only one biological replicate in
5L cells after 30 min treatment with TCDD. A total of 3974 peptides (FDR p < 1%)
including 2807 phosphorylated peptides were identified with an ion score of ≥ 20. (Table
provided on an accompanying CD)
Table 3: List of all unique peptides identified in at least two biological replicates
in 5L cells after 1 hour treatment with TCDD. A total of 1717 peptides (FDR
p < 1%) including 1105 phosphorylated peptides were identified with an ion score of ≥ 20.
(Table provided on an accompanying CD)
Table 4: List of all unique peptides identified in only one biological replicate in
5L cells after 1 hour treatment with TCDD. A total of 4168 peptides (FDR p < 1%)
including 2906 phosphorylated peptides were identified with an ion score of ≥ 20. (Table
provided on an accompanying CD)
Table 5: List of all unique peptides identified in at least two biological replicates
in 5L cells after 2 hours treatment with TCDD. A total of 1069 peptides (FDR
p < 1%) including 882 phosphorylated peptides were identified with an ion score of ≥ 20.
(Table provided on an accompanying CD)
Table 6: List of all unique peptides identified in only one biological replicate in
5L cells after 2 hours treatment with TCDD. A total of 2710 peptides (FDR p < 1%)
including 2116 phosphorylated peptides were identified with an ion score of ≥ 20. (Table
provided on an accompanying CD)
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Table 7: List of unique identified peptides found regulated at least at one time
point. In total 30 different proteins were identified, which showed alterations of at least one
phosphosite after treatment with TCDD for 30 min, 1 hour or 2 hours. The table includes
phosphorylated peptides identified as significantly regulated in a minimum of two biological
replicates (7 different peptides) per time point as well as peptides found regulated in only
one replicate per time point. For every peptide the IPI and Uniprot accession, protein
name, peptide sequence with phosphorylation assignment, the phosphosite localization
within the protein and the different normalized ratios are shown. (Table provided on an
accompanying CD)
Table 8: List of unique identified regulated phosphopeptides and co-analysed
peptides belonging to the same protein. The table shows the phosphopeptides iden-
tified as regulated after TCDD treatment for 30 min, 1 hour or 2 hours and all other pep-
tides belonging to the same protein. For every peptide the IPI accession, protein name
and molecular weight, peptide sequence with phosphorylation assignment and the different
normalized ratios (median) are shown. (Table provided on an accompanying CD)
Table 9: Detailed overview of known, ”known by similarity” or novel phos-
phosites identified. The table shows the phosphopeptides that could be mapped to a
Swiss-Prot accession number with the information whether the identified phosphorylation
site is known, ”known by similarity” or novel. For every peptide the IPI and Swiss-Prot
accession, protein name, peptide sequence with phosphorylation assignment and the phos-
phosite localization within the protein are shown. (Table provided on an accompanying
CD)
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Appendix B Figures
APPENDIX B. FIGURES
(a) 1 hour DMSO/TCDD; Biological Replicate 1 (b) 1 hour DMSO/TCDD; Biological Replicate 2
(c) 1 hour DMSO/TCDD; Biological Replicate 3
Figure 1: MA plots of peptides before normalization from the 1 hour data set.
Unnormalized peptide ratios were plotted as ratios-vs-average (MA) plots. The log2 ratios
H/L (y-axis) are plotted against the log2 average of the peptide intensities H (heavy =
TCDD treated) and L (light = control). The blue line is a lowess line, the red line indicates
y = 0. a), b) and c) show the data for the three different biological replicates obtained
after treatment of the cells with DMSO/TCDD for 1 hour.
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(a) 1 hour DMSO/TCDD; Biological Replicate 1 (b) 1 hour DMSO/TCDD; Biological Replicate 2
(c) 1 hour DMSO/TCDD; Biological Replicate 3
Figure 2: MA plots of peptides after normalization from the 1 hour data set.
Normalized peptide ratios were plotted as ratios-vs-average (MA) plots. The log2 ratios
H/L (y-axis) are plotted against the log2 average of the peptide intensities H (heavy =
TCDD treated) and L (light = control). The red line indicates y = 0. a), b) and c) show
the data for the three different biological replicates obtained after treatment of the cells
with DMSO/TCDD for 1 hour.
133
APPENDIX B. FIGURES
(a) 2 hours DMSO/TCDD; Biological Replicate 1 (b) 2 hours DMSO/TCDD; Biological Replicate 2
Figure 3: MA plots of peptides before normalization from the 2 hours data set.
Unnormalized peptide ratios were plotted as ratios-vs-average (MA) plots. The log2 ratios
H/L (y-axis) are plotted against the log2 average of the peptide intensities H (heavy =
TCDD treated) and L (light = control). The blue line is a lowess line, the red line indicates
y = 0. a) and b) show the data for the two different biological replicates obtained after
treatment of the cells with DMSO/TCDD for 2 hours.
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(a) 2 hours DMSO/TCDD; Biological Replicate 1 (b) 2 hours DMSO/TCDD; Biological Replicate 2
Figure 4: MA plots of peptides after normalization from the 1 hour data set.
Normalized peptide ratios were plotted as ratios-vs-average (MA) plots. The log2 ratios
H/L (y-axis) are plotted against the log2 average of the peptide intensities H (heavy =
TCDD treated) and L (light = control). The red line indicates y = 0. a) and b) show the
data for the two different biological replicates obtained after treatment of the cells with
DMSO/TCDD for 2 hours.
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Figure 5: Annotated MS/MS spectrum of the doubly phosphorylated peptide SAPASPTH-
PGLMSPR. The peptide was found down-regulated (regulation factor of 0.62, TCDD treat-
ment of 30 min) and belongs to the protein ”similar to forkhead box K1 isoform alpha”.
* indicates a phosphoric acid loss and ++ a doubly charged peptide.
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Figure 6: Annotated MS/MS spectrum of the serine-phosphorylated peptide SGEGEVS-
GLMR. The peptide was found up-regulated (regulation factor of 1.58, TCDD treatment
of 30 min and regulation factor of 1.87, 2 hours treatment). It belongs to the protein
Transcription intermediary factor 1-beta. * indicates a phosphoric acid loss.
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Figure 7: Annotated MS/MS spectrum of the tyrosine-phosphorylated peptide IGEG-
TYGVVYK. The peptide was found up-regulated (regulation factor of 1.64, TCDD treat-
ment of 30 min) and belongs to the protein Cyclin-dependent kinase 1.
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Figure 8: Annotated MS/MS spectrum of the serine-phosphorylated peptide SESLI-
DASEDSQLEAAIR. The peptide was found up-regulated (regulation factor of 1.86, TCDD
treatment of 30 min) and belongs to the protein UBX domain-containing protein 7.
* indicates a phosphoric acid loss.
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Figure 9: Annotated MS/MS spectrum of the serine-phosphorylated peptide LPSGS-
GAASPTTGSAVDIR. The peptide was found up-regulated (regulation factor of 1.98,
TCDD treatment of 1 hour and regulation factor of 1.60, 2 hours treatment). It belongs to
the protein similar to AHNAK nucleoprotein isoform 1 isoform 2. * indicates a phosphoric
acid loss.
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Figure 10: Annotated MS/MS spectrum of the serine-phosphorylated peptide SMSAD-
EDLQEPSR. The peptide were found up-regulated (regulation factor of 1.64, TCDD treat-
ment of 1 hour and regulation factor of 1.75, 2 hours treatment). It belongs to the protein
RD RNA-binding protein. * indicates a phosphoric acid loss.
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Figure 11: Annotated MS/MS spectrum of the serine-phosphorylated peptide SLSE-
QPVVDTATATEQAK. The peptide was found up-regulated (regulation factor of 2.79,
TCDD treatment of 1 hour and belongs to the protein RD RNA-binding protein.
* indicates a phosphoric acid loss.
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Figure 12: Annotated MS/MS spectrum of the serine-phosphorylated peptide VD-
DDSLGEFPVTNSR. The peptide was found down-regulated (regulation factor of 0.56,
TCDD treatment of 1 hour) and belongs to the protein Dpf2 protein. * indicates a phos-
phoric acid loss.
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Figure 13: Annotated MS/MS spectrum of the serine-phosphorylated peptide
RHSVTLPSSK. The peptide was found up-regulated (regulation factor of 1.50, TCDD
treatment of 1 hour) and belongs to the protein Zfp36l1 Butyrate response factor 1.
* indicates a phosphoric acid loss and ++ a doubly charged peptide.
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Figure 14: Annotated MS/MS spectrum of the threonine-phosphorylated peptide NTEL-
CETPTTSDPK. The peptide was found up-regulated (regulation factor of 1.63, TCDD
treatment of 1 hour and regulation factor of 1.51, 2 hours treatment). It belongs to the
protein UBX domain-containing protein 4.
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Figure 15: Annotated MS/MS spectrum of the non-phosphorylated peptide NTEL-
CETPTTSDPK. The peptide was found not regulated (regulation factor of 0.87, TCDD
treatment of 1 hour) and belongs to the protein UBX domain-containing protein 4.
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Figure 16: Annotated MS/MS spectrum of the serine-phosphorylated peptide FNSYDISR.
The peptide was found up-regulated (regulation factor of 1.65, TCDD treatment of 1 hour)
and belongs to the protein Dennd5a protein. * indicates a phosphoric acid loss.
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Figure 17: Annotated MS/MS spectrum of the serine-phosphorylated peptide TFS-
RDEVHGQDSGAEDSISK. The peptide was found up-regulated (regulation factor of
1.73, TCDD treatment of 1 hour) and belongs to the protein Kinesin-like protein KIF4.
* indicates a phosphoric acid loss and ++ a doubly charged peptide.
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Figure 18: Annotated MS/MS spectrum of the serine-phosphorylated peptide LSSQL-
SAGEEK. The peptide was found up-regulated (regulation factor of 1.99, TCDD treat-
ment of 1 hour and regulation factor of 1.81, 2 hours treatment). It belongs to the protein
LYRIC. * indicates a phosphoric acid loss and ++ a doubly charged peptide.
149
APPENDIX B. FIGURES
Figure 19: Annotated MS/MS spectrum of the serine-phosphorylated peptide FARSDDE-
QSSADK. The peptide was found up-regulated (regulation factor of 2.44, TCDD treatment
of 1 hour and regulation factor of 3.67, 2 hours treatment). It belongs to the protein ARNT.
* indicates a phosphoric acid loss.
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Figure 20: Annotated MS/MS spectrum of the serine-phosphorylated peptide SNSSEASS-
GDFLDLK. The peptide was found up-regulated (regulation factor of 1.49, TCDD treat-
ment of 2 hours) and belongs to the protein Hematological and neurological expressed 1
protein. * indicates a phosphoric acid loss.
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Figure 21: Annotated MS/MS spectrum of the serine-phosphorylated peptide ALDIDS-
DEEPEPK. The peptide was found down-regulated (regulation factor of 0.64, TCDD treat-
ment of 2 hours) and belongs to the protein Uncharacterized protein, Sgef. * indicates a
phosphoric acid loss.
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Figure 22: Annotated MS/MS spectrum of the threonine-phosphorylated peptide
QGDETPSTNNGSDDEK. The peptide was found down-regulated (regulation factor of
0.51, TCDD treatment of 2 hours) and belongs to the protein Uncharacterized protein,
Rabgap1. * indicates a phosphoric acid loss.
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Figure 23: Annotated MS/MS spectrum of the serine-phosphorylated peptide
EQSSSPSEPNPNPELR. The peptide was found down-regulated (regulation factor of
0.59, TCDD treatment of 2 hours) and belongs to the protein Cdc42 effector protein 1.
* indicates a phosphoric acid loss.
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Figure 24: Annotated MS/MS spectrum of the serine-phosphorylated peptide LY-
VAQQMAPPSPR. The peptide was found down-regulated (regulation factor of 0.61,
TCDD treatment of 2 hours) and belongs to the protein RNA binding motif, single stranded
interacting protein 2. * indicates a phosphoric acid loss.
155
APPENDIX B. FIGURES
Figure 25: Annotated MS/MS spectrum of the doubly phosphorylated peptide TNSP-
SASPSVLSNAEHK. The peptide was found down-regulated (regulation factor of 0.62,
TCDD treatment of 2 hours) and belongs to the protein Ataxin-2. * indicates a phospho-
ric acid loss and ++ a doubly charged peptide.
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Figure 26: Annotated MS/MS spectrum of the serine-phosphorylated peptide SASLSNLH-
SLDR. The peptide was found down-regulated (regulation factor of 0.65, TCDD treatment
of 2 hours) and belongs to the protein Chibby homolog 1. * indicates a phosphoric acid
loss and ++ a doubly charged peptide.
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Figure 27: Annotated MS/MS spectrum of the serine-phosphorylated peptide GSPPVPS-
GPPMEEDGLR. The peptide was found down-regulated (regulation factor of 0.67, TCDD
treatment of 2 hours) and belongs to the protein Senp3 protein. * indicates a phosphoric
acid loss and ++ a doubly charged peptide.
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Figure 28: Annotated MS/MS spectrum of the serine-phosphorylated peptide LATKPETS-
FEEGDGR. The peptide was found up-regulated (regulation factor of 1.54, TCDD treat-
ment of 2 hours) and belongs to the protein Uncharacterized protein, Ppfibp1. * indicates
a phosphoric acid loss.
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Figure 29: Annotated MS/MS spectrum of the tyrosine-phosphorylated peptide HTD-
DEMTGYVATR. The peptide was found up-regulated (regulation factor of 1.57, TCDD
treatment of 2 hours) and belongs to the protein Mitogen-activated protein kinase 14.
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Figure 30: Annotated MS/MS spectrum of the threonine-phosphorylated peptide
SMEETRPVPTVK. The peptide was found up-regulated (regulation factor of 1.73, TCDD
treatment of 2 hours) and belongs to the protein ZZ-type with EF hand domain 1 isoform
1. * indicates a phosphoric acid loss and ++ a doubly charged peptide.
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Figure 31: Annotated MS/MS spectrum of the serine-phosphorylated peptide LLSSNED-
DASILSSPTDR. The peptide was found up-regulated (regulation factor of 1.75, TCDD
treatment of 2 hours) and belongs to the protein Mediator of RNA polymerase II tran-
scription subunit 2. * indicates a phosphoric acid loss and ++ a doubly charged peptide.
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Figure 32: Annotated MS/MS spectrum of the threonine-phosphorylated peptide GDV-
TAEEAAGASPAK. The peptide was found up-regulated (regulation factor of 1.94, TCDD
treatment of 2 hours) and belongs to the protein MARCKS-related protein. * indicates a
phosphoric acid loss.
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Figure 33: Annotated MS/MS spectrum of the serine-phosphorylated peptide
RHSYENDGGQPHK. The peptide was found up-regulated (regulation factor of 1.96,
TCDD treatment of 2 hours) and belongs to the protein Nuclear cap-binding protein sub-
unit 1. * indicates a phosphoric acid loss.
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